###begin article-title 0
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors
###end article-title 0
###begin title 1
Abstract.
###end title 1
###begin p 2
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 707 712 <span type="species:ncbi:10090">mouse</span>
###xml 963 968 <span type="species:ncbi:10090">mouse</span>
###xml 1405 1410 <span type="species:ncbi:10090">mouse</span>
Glycogen synthase 2 (Gys-2) is the ratelimiting enzyme in the storage of glycogen in liver and adipose tissue, yet little is known about regulation of Gys-2 transcription. The peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in the regulation of lipid and glucose metabolism and might be hypothesized to govern glycogen synthesis as well. Here, we show that Gys-2 is a direct target gene of PPARalpha, PPARbeta/delta and PPARgamma. Expression of Gys-2 is significantly reduced in adipose tissue of PPARalpha-/-, PPARbeta/delta-/- and PPARgamma+/- mice. Furthermore, synthetic PPARbeta/delta, and gamma agonists markedly up-regulate Gys-2 mRNA and protein expression in mouse 3T3-L1 adipocytes. In liver, PPARalpha deletion leads to decreased glycogen levels in the refed state, which is paralleled by decreased expression of Gys-2 in fasted and refed state. Two putative PPAR response elements (PPREs) were identified in the mouse Gys-2 gene: one in the upstream promoter (DR-1prom) and one in intron 1 (DR-1int). It is shown that DR-1int is the response element for PPARs, while DR-1prom is the response element for Hepatic Nuclear Factor 4 alpha (HNF4alpha). In adipose tissue, which does not express HNF4alpha, DR-1prom is occupied by PPARbeta/delta and PPARgamma, yet binding does not translate into transcriptional activation of Gys-2. Overall, we conclude that mouse Gys-2 is a novel PPAR target gene and that transactivation by PPARs and HNF4alpha is mediated by two distinct response elements.
###end p 2
###begin title 3
Keywords.
###end title 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 690 691 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1161 1162 1146 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1163 1164 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
Metabolic syndrome describes a combination of metabolic abnormalities that include central obesity, dyslipidemia, hypertension, insulin resistance, and a pro-inflammatory and pro-thrombotic state. An important group of pharmacological targets for the treatment of metabolic syndrome are the peroxisome proliferator activated receptors (PPARs). PPARs are ligand-activated transcription factors belonging to the superfamily of nuclear receptors, which include numerous cellular receptors for nutrients and steroids. So far, three PPAR isotypes (alpha, beta/delta, gamma) have been identified in a wide range of species, each displaying a different tissue distribution and ligand specificity [1]. PPARs share a similar structure and a common molecular mechanism of action by forming an obligate heterodimer with the 9-cis retinoic acid receptor RXR. PPAR-RXR heterodimers selectively bind genomic sequences consisting of a direct repeat of the hexameric nucleotide sequence AGGTCA separated by 1 nucleotide (Direct Repeat-1). These so-called peroxisome proliferator response elements (PPRE) are located in the promoter of PPAR target genes or in intronic regions [2-5].
###end p 5
###begin p 6
###xml 106 107 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 108 109 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 356 357 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 358 360 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 441 443 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 445 447 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 534 536 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 711 713 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 715 717 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1109 1111 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1113 1115 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
The PPARalpha isotype (NR1C1) is highly expressed in liver, and governs the adaptive response to fasting [6-8]. PPARalpha is an extremely important regulator of hepatic nutrient metabolism including fatty acid oxidation (peroxisomal and mitochondrial), fatty acid uptake, amino acid metabolism, glycerol metabolism, and lipoprotein assembly and transport [9-11]. In addition, PPARalpha potently suppresses the hepatic inflammatory response [12, 13], an effect that is also observed in extra-hepatic tissues such as the vascular wall [14]. Much less is known about the role of PPARalpha in other tissues, although evidence is accumulating that PPARalpha induces cardiac and skeletal muscle fatty acid oxidation [15, 16]. Importantly, PPARalpha mediates the effects of hypolipidemic fibrate drugs, which decrease plasma triglycerides and increase plasma HDL concentrations. In contrast to PPARalpha, PPARgamma (NR1C3) is highly expressed in white adipose tissue (WAT), where it promotes lipid storage. PPARgamma is a key transcription factor in the adipogenesis program and is essential for adipocyte survival [17, 18]. It also serves as the molecular target for the thiazolidine-dione (TZD) class of insulin-sensitizing drugs that are widely used in the treatment of type 2 diabetes. PPARgamma promotes whole body glucose utilization; however, it has been difficult to identify the molecular mechanisms behind this effect. Much of the attention has been focused on possible cross-talk between adipose tissue and skeletal muscle, as muscle is responsible for the major share of whole body glucose utilization. However, adipose tissue is a large organ, especially in the obese, and accordingly it can also be envisioned that the insulin-sensitizing effect of TZDs on glucose uptake is partially exerted at the adipose tissue level.
###end p 6
###begin p 7
###xml 350 352 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 353 355 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 504 506 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 738 740 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 742 744 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 878 880 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 881 883 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
While PPARalpha and PPARgamma have been extensively studied over many years, much less is known about the function of the PPARbeta/delta isotype (NR1C2). Studies with genetically modified PPARdelta/delta mice have illustrated the importance of this nuclear receptor in WAT and skeletal muscle, two organs that have a key role in glucose homeostasis [19-22]. It was shown that activation of PPARbeta/delta in adipose tissue protects against adiposity and hyperlipidemia by inducing fatty acid catabolism [21]. Moreover, pharmacological activation as well as specific constitutive over-expression of PPARbeta/delta leads to a shift in muscle fiber composition towards type I muscle fibers, resulting in increased muscle oxidative capacity [20, 22]. PPARbeta/delta has also been shown to stimulate hepatic VLDL production, influence wound healing, and affect colon carcinogenesis [23-25]. However, whether PPARdelta/delta has a functional role in glucose homeostasis, in analogy with other PPAR isotypes, remains to be firmly established.
###end p 7
###begin p 8
Here we show that glycogen synthase 2 (Gys-2), the rate-limiting enzyme for glycogen synthesis in liver and adipose tissue, is a target gene of PPARalpha, PPARbeta/delta and PPARgamma. Transcriptional regulation is achieved via a PPAR response element present in the first intron. We show that an additional direct repeat response element identified in the Gys-2 promoter mediates transactivation by hepatic nuclear factor 4alpha (HNF4alpha).
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin p 10
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chemicals</bold>
###xml 250 254 <span type="species:ncbi:9913">calf</span>
###xml 268 272 <span type="species:ncbi:9913">calf</span>
Chemicals. Wy14643 was obtained from Eagle Picher Technologies laboratories (Lenexa, KS, USA). Rosiglitazone was from Alexis (Breda, The Netherlands). SYBR Green was from Eurogentec (Seraing, Belgium). Dulbecco's modified Eagles medium (DMEM), fetal calf serum (FCS), calf serum and penicillin/streptomycin/fungizone were from Cambrex Bioscience (Seraing). Otherwise, chemicals were from Sigma (Zwijndrecht, The Netherlands).
###end p 10
###begin p 11
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Animal experiments</bold>
###xml 198 200 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 202 204 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 549 558 511 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 572 573 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 592 601 550 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 615 616 573 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 630 632 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">Mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
Animal experiments. PPARbeta/delta mutant null mice (PPARbeta/delta-/-) and PPARgamma heterozygous mice (PPARgamma+/-) were on a mixed background (Svl29/C57BL/6) and have been described previously [26, 27]. Wild-type littermates served as control animals. PPARalpha-/- mice and corresponding wild-type mice on an Svl29 background were purchased at Jackson Laboratories (Bar Harbor, ME, USA). Liver-specific hepatocyte nuclear factor 4alpha (HNF4alpha)-null mice were generated as described previously. Livers were collected from 45-day-old HNF4alphaflox/flox X albumin-Cre+ (KO) and HNF4alphaflox/flox X albumin-Cre- (FLOX) mice [28]. Mice were maintained at 20degreesC with a 12-h light-dark cycle. All mice were between 3 and 6 months of age. For the fasting experiment, 3-month-old male mice were fasted for different periods of time starting at the onset of the light cycle. For the refeeding experiment, mice were fasted for 24 h after which they were put back on chow for 7 h before sacrifice. After sacrificing the animals, tissues were immediately frozen in liquid nitrogen. The animal experiments were approved by the animal experimentation committee of Wageningen University or the Etat de Vaud (Switzerland).
###end p 11
###begin p 12
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Oligonucleotide micro-array</bold>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 518 523 <span type="species:ncbi:10090">mouse</span>
Oligonucleotide micro-array. Total RNA was prepared from epididymal WAT of wild-type and PPARbeta/delta-/- mice (five animals of each genotype) using TRIzol reagent (Invitrogen, Breda, The Netherlands) and subsequently pooled per group. Pooled RNA was further purified using Qiagen RNeasy columns, and the quality was verified using Bioanalyzer 2100 (Agilent, Amsterdam). For one cycle cRNA synthesis (Affymetrix, Santa Clara, USA) 10 microg of RNA was used. Hybridization, washing and scanning of Affymetrix GeneChip mouse genome 430 2.0 arrays was according to standard Affymetrix protocols. Fluorimetric data were processed by Affymetrix GeneChip operating software and the gene chips were globally scaled to all the probe sets with an identical target intensity value. Further analysis was performed by Data Mining Tool (Affymetrix).
###end p 12
###begin p 13
###xml 0 25 0 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink">3T3-L1 adipogenesis assay</bold>
###xml 75 79 <span type="species:ncbi:9913">calf</span>
3T3-L1 adipogenesis assay. 3T3-L1 fibroblasts were grown in DMEM plus 10 % calf serum and plated for final differentiation in DMEM plus 10 % FCS. At 2 days after reaching confluence, the medium was changed and the following compounds were added: isobutyl methylxanthine (0.5 mM), dexamethasone (1 microM), and insulin (5 microg/mL). After 3 days, the medium was changed to DMEM plus 10% FCS and insulin (5 microg/mL). After 6 days the medium was changed to DMEM plus 10% FCS, which was changed every 3 days.
###end p 13
###begin p 14
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primary mouse or rat hepatocyte isolation</bold>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 796 797 796 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 17 20 <span type="species:ncbi:10116">rat</span>
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
###xml 61 64 <span type="species:ncbi:10116">rat</span>
Primary mouse or rat hepatocyte isolation. Primary mouse and rat hepatocytes were isolated as described previously [29]. Briefly, after cannulation of the portal vein, the liver was perfused with calcium-free HBSS, which was pre-gassed with 95 % O2 /5 % CO2. Next, the liver was perfused with a collagenase solution until swelling and degradation of the internal liver structure was observed. The hepatocytes were released, filtered and washed several times using Krebs buffer. The viability was assessed by tryptan blue staining and was at least 80 %. Cells were cultured in William's Medium E supplemented with 10% FCS, penicillin/streptomycin/fungizone, insulin and dexamethasone. Cells were plated in collagen (Serva Feinbiochemica, Heidelberg, Germany) -coated wells with a density of 0.5x106 cells/ml. After 4 h of incubation, the medium was removed and replaced with fresh medium. The next day, hepatocytes were used for experiments.
###end p 14
###begin p 15
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RNA isolation, reverse-transcription, and real-time quantitative PCR</bold>
RNA isolation, reverse-transcription, and real-time quantitative PCR. Total RNA was extracted from tissues with TRIzol reagent (Invitrogen); 1 microg total RNA was then reverse-transcribed with iScript (Bio-Rad, Veenendaal, The Netherlands). cDNA was PCR-amplified with Platinum Taq DNA polymerase (Invitrogen) on a Bio-Rad iCycler or MylQ PCR machine. Primers were designed to generate a PCR amplification product of 100-200 bp and were taken from Primerbank (). Specificity of the amplification was verified by melt curve analysis and evaluation of efficiency of PCR amplification. Expression was related to the control gene 36B4, which did not change under any of the experimental conditions studied.
###end p 15
###begin p 16
The following primer pairs were used: mGys-2 (forward): CCAGCTTGACAAGTTCGACA, mGys-2 (reverse): AT-CAGGCTTCCTCTTCAGCA, m36B4 (forward): AGCGCGTCCTGGCATTGTGTGG, m36B4 (reverse): GGGCAGCAGTGGTGGCAGCAGC, mPPARalpha (forward): TATTCGGCTGAAGCTGGTGTAC, mPPARalpha (reverse): CTGGCATTTGTTCCGGTTCT, mPPARbeta (forward): TTGAGCCCAAGTTCGAGTTTG, mPPARbeta (reverse): CGGTCTCCACACAGAATGATG, mPPARgamma (forward): CA-CAATGCCATCAGGTTTGG, mPPARgamma (reverse): GCTGGTCGATATCACTGGAGATC.
###end p 16
###begin p 17
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Transactivation assay</bold>
###xml 326 333 326 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hindlll</italic>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpnl</italic>
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
Transactivation assay. The proximal part of the mouse Gys-2 promoter was PCR amplified from mouse genomic DNA (strain C57BL/6) using the forward primer: 5' CTTGCTGCCTTTCAG-GAGAGGGCAG 3' and reverse primer: 5' TTCTCTTTAGC-CATTA AG ATAG 3'. The resulting 553-bp fragment was used for a second PCR amplification step introducing Hindlll and Kpnl sites, which were used for subcloning into the pGL-3 Basic vector (Invitrogen).
###end p 17
###begin p 18
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpnl/Bg</italic>
###xml 537 541 537 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpnl</italic>
###xml 546 551 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bglll</italic>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 192 196 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 439 444 <span type="species:ncbi:10090">mouse</span>
###xml 479 484 <span type="species:ncbi:10090">mouse</span>
###xml 630 635 <span type="species:ncbi:9606">human</span>
###xml 1390 1395 <span type="species:ncbi:10090">mouse</span>
A 156-bp nucleotide fragment surrounding the putative PPRE within the mGys-2 promoter was PCR amplified from mouse genomic DNA (strain C57BL/6) and subcloned into Kpnl/Bg/II sites of the pGL3 SV40 promoter vector (pGL3-tk-LUC, Promega, Leiden, The Netherlands) using the forward primer: 5'AAATCG-CAGCTGAAACCT 3', and reverse primer: 5' CTCCTGCTTGTGCTTCTGC 3'. A 314-nucleotide fragment surrounding the putative PPRE within intron 1 of the mouse Gys-2 gene was PCR amplified from mouse genomic DNA (strain C57BL/6) and subcloned into the Kpnl and Bglll sites of the pGL-Tk-Luc reporter gene. Reporter vectors were transfected into human hepatoma HepG2 cells, together with an expression vector (pSG5) for mPPARalpha, mPPARbeta, or mPPARyl, in the presence or absence of Wy14643 (50 microM), L-165041 (5 microM), or rosiglitazone (5 microM), respectively. Transfections were carried out using the calcium-phosphate precipitation method. A beta-galactosidase reporter vector was co-transfected to normalize for differences in transfection efficiency. Luciferase activity was measured 24 h post transfection using the Promega luciferase assay kit (Promega) on a Fluoroskan Ascent Fl apparatus (Thermo labsystems, Breda, The Netherlands). beta-Galactosidase activity was measured in the cell lysate by a standard assay using 2-nitrophenyl-betaD-galactopyrano-side as a substrate. To disable the mouse Gys-2 PPRE within the mGys-2 promoter, two separate (A and B) partially overlapping PCR fragments were generated using the wild-type mGys-2 promoter as a template. Primers sets used to generate part A of the mutated mGys-2 promoter fragment were: 5'-TTTGGTCTAAAGGCCTTTGGCCAAAGG-3' and 5'-CTTGCTGCCTTTCAGGAGAGGGC
###end p 18
###begin p 19
###xml 403 406 403 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 411 414 411 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 791 795 787 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NotI</italic>
###xml 532 537 <span type="species:ncbi:9606">human</span>
AG-3'. Primers sets used to generate part B of the mutated mGys-2 promoter fragment were: 5'-CCTTTGGCCAAAGGCCTTTA-GACCAAA-3' and 5'-TTCTCTTTAGCCATTAAGATAGG-GATTG-3'. PCR was carried-out using the two upper DNA fragments and the following primers: 5'- cccaagcttCTTGCTGCCTTTCAGGAG-3' and 5'- ggggtaccTTCTCTTTAGCCATTAAGATAG-3'. The PCR fragment was subsequently cloned into the pGL3 basic reporter vector (HindIII/KpnI cloning site) and verified by automated sequencing. The hHNF4alpha expression plasmid was constructed by amplifying human hepatoma HepG2 cDNA using the following primers, forward primer 5'-GAATGCGACTCTCCAAAACC-3' and reverse primer 5'-ATCCTTCCCATTCCTGCTCT-3', followed by subcloning of the resulting PCR product into an pGEM-Teasy vector (Promega). The insert was excised by NotI digestion and further subcloned into pcDNA3.1/V5-HisA (Invitrogen). The nucleotide sequence was verified by automated sequencing.
###end p 19
###begin p 20
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gel shift</bold>
###xml 112 120 104 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 599 601 587 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 663 671 651 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
Gel shift. hRXRalpha and mPPARgamma proteins were generated from pSG5 expression vectors, using the TNT coupled in vitro transcription/translation system (Promega). The following oligos were annealed to generate the double-stranded DNA probe; for DR-lint: 5'-CAGGACTTTGGTGACCTCTGGCCTATAT-3' and 5'-ACACATATAGGCCAGAGGTCACCAAAGTC-3'. For nonspecific competition, the following primers were used: etsF 5'-TGGAATGTACCGGAAATAACACCA-3', etsR 5'- TGGTGTTATTTCCGGTACATTCCA-3'. Oligonucleotides were annealed and labeled by Klenow filling (New England Biolabs, Leusden, The Netherlands) using Redivue [alpha-32P]dCTP (3000 Ci/mmol; Amersham, Roosendaal, The Netherlands). In vitro-translated proteins (0.5-0.8 microl/reaction) were pre-incubated for 15 min on ice in 1x binding buffer (80 mM KCl, 1 mM DTT, 10 mM Tris-HCl pH 7.4, 10 % glycerol, plus protease inhibitors) in presence of 2 microg poly[dI.dC], 5 microg sonicated salmon sperm DNA and competitor oligonucleotides in a final volume of 20 microl. Then 1 ng (1 ng/microl) of radiolabeled oligo was added and incubation was continued for another 10 min at room temperature. Complexes were separated on a 4 % Polyacrylamide gel (acrylamide/bisacrylamide 37.5:1) equilibrated in 0.5x TBE at 25 mA.
###end p 20
###begin p 21
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chromatin immunoprecipitation</bold>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
###xml 582 585 <span type="species:ncbi:10116">rat</span>
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) on 3T3-L1 cells and mouse liver was carried out as described previously [11]. Sequences of primers used for PCR were 5'-TCTGGCAGGCATAAGGACCCGAGTT-3' and 5'- GGAAGCCAGGACAGAGTGCAAATACAAT-3' for DR-lint (Intron). For DR-lprom, the following primers were used: 5'-AAAACTGCTTGTGTCTGAGGGAAAC-3' and 5'-AGAG-GACAGACTGAGCATGACAAGAG-3'. Control primers used were 5'-GCTGCGAGATCCATCACCCACTAAAC-3' and 5'-AGCCATCTCACCAGCCCCAACTT-3'. Antibodies against PPARs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ChIP on rat hepatocytes was done using a commercially available kit (Active Motif, Rixensart, Belgium). The HNF4alpha antibody was from Tebu-Bio (Heerhugowaard, The Netherlands). The primers used to amplify the sequence surrounding the DR-lprom were 5-GAATGCCGCTGTGCCTGAGGGAAAC-3' and 5'-AGAGGACAGAAGAAGAGTGACAAGAG-3'. For DR-lint: 5'-TCTGTCAGGCATAAGGACCTGGGTT-3' and 5'-ATTGTATTTGAACTCTGTCCTGGTCTCT-3'.
###end p 21
###begin p 22
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Histology</bold>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Histology. Liver tissue from wild-type and PPARalpha-/- mice was embedded in Tissue-Tek O.C.T compound from Sakura Finetek (Zoeterwoude, The Netherlands) and frozen. Cryosections of 5 microm from frozen liver were made and analyzed for glycogen accumulation using the periodic acid-Schiff (PAS) reaction. Hematoxylin and eosin staining of liver cryosections was done using standard protocols.
###end p 22
###begin p 23
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Western blot</bold>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 287 292 <span type="species:ncbi:10090">mouse</span>
Western blot. A mouse anti-glycogen synthase monoclonal antibody was used (clone GS-7H5 MAB3106) (Chemicon International, Hampshire, UK). Western blotting was carried out as previously described [4]. The primary antibody was used at a dilution of 1:1000 and the secondary antibody (anti-mouse IgG, Dako, Glostrup, Denmark) was used at a dilution of 1:8000.
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
Expression of Gys-2 in WAT is regulated by PPARs.
###end title 25
###begin p 26
###xml 147 153 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 460 461 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 710 712 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">la</xref>
###xml 1057 1060 987 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1134 1136 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">lb</xref>
###xml 1326 1334 1249 1257 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 1</label>
###xml 1496 1497 1419 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1510 1511 1433 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1537 1540 1453 1456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1556 1559 1468 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1579 1582 1487 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1676 1677 1584 1585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1687 1688 1595 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1722 1723 1630 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1729 1730 1637 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2075 2076 1972 1973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1334 2252 1257 2130 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Expression of Glycogen synthase 2 (Gys-2) in white adipose tissue (WAT) is regulated by peroxisome proliferator-activated receptors (PPARs). Expression of Gys-2 (<italic>a</italic>) and PPARs (<italic>b</italic>) in WAT of PPAR&#946;/&#948;<sup>-/-</sup> mice, PPAR&#947;<sup>+/&#8722;</sup> mice, and PPAR&#945;<sup>-/-</sup>mice, as determined by qPCR. The effects of PPAR deletion were evaluated by Student&#8217;s Mest (* <italic>p</italic>&lt;0.05; ** <italic>p</italic>&lt;0.01). Error bars represent SEM (<italic>n</italic>=5). (<italic>c</italic>) Differentiated 3T3-L1 adipocytes were treated with the synthetic PPAR&#947; agonists rosiglitazone or ciglitazone, or the PPAR&#946;/&#948; agonist L165041 for 24 h. Expression of Gys-2 was determined by qPCR. Expression of cells treated with vehicle (DMSO) was set at 1. Data shown are representative results from three independent experiments, (<italic>d</italic>) Gys protein expression was analyzed in lysates from 3T3-L1 adipocytes treated with either PPAR&#946;/&#948; (L165041, 2.5 &#181;M) or PPAR&#947; (rosiglitazone, 1 &#181;M) agonist.</p>
###xml 1334 2252 1257 2130 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Expression of Glycogen synthase 2 (Gys-2) in white adipose tissue (WAT) is regulated by peroxisome proliferator-activated receptors (PPARs). Expression of Gys-2 (<italic>a</italic>) and PPARs (<italic>b</italic>) in WAT of PPAR&#946;/&#948;<sup>-/-</sup> mice, PPAR&#947;<sup>+/&#8722;</sup> mice, and PPAR&#945;<sup>-/-</sup>mice, as determined by qPCR. The effects of PPAR deletion were evaluated by Student&#8217;s Mest (* <italic>p</italic>&lt;0.05; ** <italic>p</italic>&lt;0.01). Error bars represent SEM (<italic>n</italic>=5). (<italic>c</italic>) Differentiated 3T3-L1 adipocytes were treated with the synthetic PPAR&#947; agonists rosiglitazone or ciglitazone, or the PPAR&#946;/&#948; agonist L165041 for 24 h. Expression of Gys-2 was determined by qPCR. Expression of cells treated with vehicle (DMSO) was set at 1. Data shown are representative results from three independent experiments, (<italic>d</italic>) Gys protein expression was analyzed in lysates from 3T3-L1 adipocytes treated with either PPAR&#946;/&#948; (L165041, 2.5 &#181;M) or PPAR&#947; (rosiglitazone, 1 &#181;M) agonist.</p></caption>
###xml 2252 2252 2130 2130 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig1" id="MO1"/>
###xml 1326 2252 1249 2130 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Figure 1</label><caption><p textid="27">Expression of Glycogen synthase 2 (Gys-2) in white adipose tissue (WAT) is regulated by peroxisome proliferator-activated receptors (PPARs). Expression of Gys-2 (<italic>a</italic>) and PPARs (<italic>b</italic>) in WAT of PPAR&#946;/&#948;<sup>-/-</sup> mice, PPAR&#947;<sup>+/&#8722;</sup> mice, and PPAR&#945;<sup>-/-</sup>mice, as determined by qPCR. The effects of PPAR deletion were evaluated by Student&#8217;s Mest (* <italic>p</italic>&lt;0.05; ** <italic>p</italic>&lt;0.01). Error bars represent SEM (<italic>n</italic>=5). (<italic>c</italic>) Differentiated 3T3-L1 adipocytes were treated with the synthetic PPAR&#947; agonists rosiglitazone or ciglitazone, or the PPAR&#946;/&#948; agonist L165041 for 24 h. Expression of Gys-2 was determined by qPCR. Expression of cells treated with vehicle (DMSO) was set at 1. Data shown are representative results from three independent experiments, (<italic>d</italic>) Gys protein expression was analyzed in lysates from 3T3-L1 adipocytes treated with either PPAR&#946;/&#948; (L165041, 2.5 &#181;M) or PPAR&#947; (rosiglitazone, 1 &#181;M) agonist.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig1" id="MO1"/></fig>
###xml 2252 2259 2130 2137 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</label>
###xml 2401 2404 2272 2275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 2259 2410 2137 2281 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Genes involved in glucose and lipid metabolism that were differentially expressed between white adipose tissue of wild-type and PPAR&#946;/&#948;<sup>-/-</sup> mice.</p>
###xml 2259 2410 2137 2281 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Genes involved in glucose and lipid metabolism that were differentially expressed between white adipose tissue of wild-type and PPAR&#946;/&#948;<sup>-/-</sup> mice.</p></caption>
###xml 2410 2414 2281 2285 <th xmlns:xlink="http://www.w3.org/1999/xlink">Gene</th>
###xml 2414 2421 2285 2292 <th xmlns:xlink="http://www.w3.org/1999/xlink">Product</th>
###xml 2421 2446 2292 2317 <th xmlns:xlink="http://www.w3.org/1999/xlink">Fold decrease Micro-array</th>
###xml 2446 2451 2317 2322 <th xmlns:xlink="http://www.w3.org/1999/xlink">Q-PCR</th>
###xml 2410 2451 2281 2322 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Gene</th><th>Product</th><th>Fold decrease Micro-array</th><th>Q-PCR</th></tr>
###xml 2410 2451 2281 2322 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Gene</th><th>Product</th><th>Fold decrease Micro-array</th><th>Q-PCR</th></tr></thead>
###xml 2451 2469 2322 2340 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Glucose metabolism</td>
###xml 2451 2469 2322 2340 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Glucose metabolism</td></tr>
###xml 2469 2473 2340 2344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gys2</italic>
###xml 2469 2473 2340 2344 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Gys2</italic></td>
###xml 2473 2492 2344 2363 <td xmlns:xlink="http://www.w3.org/1999/xlink">glycogen synthase 2</td>
###xml 2492 2497 2363 2368 <td xmlns:xlink="http://www.w3.org/1999/xlink">13.27</td>
###xml 2497 2501 2368 2372 <td xmlns:xlink="http://www.w3.org/1999/xlink">9.28</td>
###xml 2469 2501 2340 2372 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Gys2</italic></td><td>glycogen synthase 2</td><td>13.27</td><td>9.28</td></tr>
###xml 2501 2507 2372 2378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3r1</italic>
###xml 2501 2507 2372 2378 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Pik3r1</italic></td>
###xml 2507 2583 2378 2454 <td xmlns:xlink="http://www.w3.org/1999/xlink">phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td>
###xml 2583 2587 2454 2458 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.99</td>
###xml 2587 2587 2458 2458 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2501 2587 2372 2458 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.99</td><td/></tr>
###xml 2587 2593 2458 2464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3r1</italic>
###xml 2587 2593 2458 2464 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Pik3r1</italic></td>
###xml 2593 2669 2464 2540 <td xmlns:xlink="http://www.w3.org/1999/xlink">phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td>
###xml 2669 2673 2540 2544 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.64</td>
###xml 2673 2673 2544 2544 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2587 2673 2458 2544 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.64</td><td/></tr>
###xml 2673 2677 2544 2548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gys3</italic>
###xml 2673 2677 2544 2548 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Gys3</italic></td>
###xml 2677 2703 2548 2574 <td xmlns:xlink="http://www.w3.org/1999/xlink">glycogen synthase 3, brain</td>
###xml 2703 2707 2574 2578 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.25</td>
###xml 2707 2707 2578 2578 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2673 2707 2544 2578 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Gys3</italic></td><td>glycogen synthase 3, brain</td><td>2.25</td><td/></tr>
###xml 2707 2714 2578 2585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppp1r3c</italic>
###xml 2707 2714 2578 2585 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Ppp1r3c</italic></td>
###xml 2714 2789 2585 2660 <td xmlns:xlink="http://www.w3.org/1999/xlink">protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td>
###xml 2789 2793 2660 2664 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.19</td>
###xml 2793 2793 2664 2664 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2707 2793 2578 2664 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>2.19</td><td/></tr>
###xml 2793 2799 2664 2670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Slc2a4</italic>
###xml 2793 2799 2664 2670 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Slc2a4</italic></td>
###xml 2799 2866 2670 2737 <td xmlns:xlink="http://www.w3.org/1999/xlink">solute carrier family 2 (facilitated glucose transporter), member 4</td>
###xml 2866 2870 2737 2741 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.16</td>
###xml 2870 2874 2741 2745 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.56</td>
###xml 2793 2874 2664 2745 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.16</td><td>1.56</td></tr>
###xml 2874 2880 2745 2751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Slc2a4</italic>
###xml 2874 2880 2745 2751 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Slc2a4</italic></td>
###xml 2880 2947 2751 2818 <td xmlns:xlink="http://www.w3.org/1999/xlink">solute carrier family 2 (facilitated glucose transporter), member 4</td>
###xml 2947 2951 2818 2822 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.04</td>
###xml 2951 2955 2822 2826 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.56</td>
###xml 2874 2955 2745 2826 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.04</td><td>1.56</td></tr>
###xml 2955 2960 2826 2831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PFK-2</italic>
###xml 2955 2960 2826 2831 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PFK-2</italic></td>
###xml 2960 3012 2831 2883 <td xmlns:xlink="http://www.w3.org/1999/xlink">6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase</td>
###xml 3012 3016 2883 2887 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.01</td>
###xml 3016 3016 2887 2887 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2955 3016 2826 2887 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>PFK-2</italic></td><td>6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase</td><td>2.01</td><td/></tr>
###xml 3016 3020 2887 2891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gdc1</italic>
###xml 3016 3020 2887 2891 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Gdc1</italic></td>
###xml 3020 3073 2891 2944 <td xmlns:xlink="http://www.w3.org/1999/xlink">glycerol phosphate dehydrogenase 1, cytoplasmic adult</td>
###xml 3073 3077 2944 2948 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.93</td>
###xml 3077 3077 2948 2948 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3016 3077 2887 2948 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Gdc1</italic></td><td>glycerol phosphate dehydrogenase 1, cytoplasmic adult</td><td>1.93</td><td/></tr>
###xml 3077 3084 2948 2955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppp1r3c</italic>
###xml 3077 3084 2948 2955 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Ppp1r3c</italic></td>
###xml 3084 3159 2955 3030 <td xmlns:xlink="http://www.w3.org/1999/xlink">protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td>
###xml 3159 3163 3030 3034 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.91</td>
###xml 3163 3163 3034 3034 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3077 3163 2948 3034 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>1.91</td><td/></tr>
###xml 3163 3167 3034 3038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gdc1</italic>
###xml 3163 3167 3034 3038 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Gdc1</italic></td>
###xml 3167 3218 3038 3089 <td xmlns:xlink="http://www.w3.org/1999/xlink">glycerolphosphate dehydrogenase 1, cytoplasmicadult</td>
###xml 3218 3222 3089 3093 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.84</td>
###xml 3222 3222 3093 3093 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3163 3222 3034 3093 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Gdc1</italic></td><td>glycerolphosphate dehydrogenase 1, cytoplasmicadult</td><td>1.84</td><td/></tr>
###xml 3222 3226 3093 3097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pygl</italic>
###xml 3222 3226 3093 3097 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Pygl</italic></td>
###xml 3226 3254 3097 3125 <td xmlns:xlink="http://www.w3.org/1999/xlink">liver glycogen phosphorylase</td>
###xml 3254 3258 3125 3129 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.71</td>
###xml 3258 3258 3129 3129 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3222 3258 3093 3129 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Pygl</italic></td><td>liver glycogen phosphorylase</td><td>1.71</td><td/></tr>
###xml 3258 3274 3129 3145 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Lipid metabolism</td>
###xml 3258 3274 3129 3145 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Lipid metabolism</td></tr>
###xml 3274 3279 3145 3150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pparg</italic>
###xml 3274 3279 3145 3150 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Pparg</italic></td>
###xml 3279 3327 3150 3198 <td xmlns:xlink="http://www.w3.org/1999/xlink">peroxisome proliferator activator receptor gamma</td>
###xml 3327 3331 3198 3202 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.99</td>
###xml 3331 3335 3202 3206 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.63</td>
###xml 3274 3335 3145 3206 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Pparg</italic></td><td>peroxisome proliferator activator receptor gamma</td><td>2.99</td><td>3.63</td></tr>
###xml 3335 3338 3206 3209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5D</italic>
###xml 3335 3338 3206 3209 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C5D</italic></td>
###xml 3338 3358 3209 3229 <td xmlns:xlink="http://www.w3.org/1999/xlink">sterol-C5-desaturase</td>
###xml 3358 3362 3229 3233 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.85</td>
###xml 3362 3362 3233 3233 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3335 3362 3206 3233 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>C5D</italic></td><td>sterol-C5-desaturase</td><td>2.85</td><td/></tr>
###xml 3362 3366 3233 3237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lrp1</italic>
###xml 3362 3366 3233 3237 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Lrp1</italic></td>
###xml 3366 3416 3237 3287 <td xmlns:xlink="http://www.w3.org/1999/xlink">low density lipoprotein receptor-related protein 1</td>
###xml 3416 3420 3287 3291 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.22</td>
###xml 3420 3420 3291 3291 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3362 3420 3233 3291 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Lrp1</italic></td><td>low density lipoprotein receptor-related protein 1</td><td>2.22</td><td/></tr>
###xml 3420 3424 3291 3295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd36</italic>
###xml 3420 3424 3291 3295 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cd36</italic></td>
###xml 3424 3436 3295 3307 <td xmlns:xlink="http://www.w3.org/1999/xlink">CD36 antigen</td>
###xml 3436 3440 3307 3311 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.20</td>
###xml 3440 3445 3311 3316 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.09]</td>
###xml 3420 3445 3291 3316 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Cd36</italic></td><td>CD36 antigen</td><td>2.20</td><td>3.09]</td></tr>
###xml 3445 3450 3316 3321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fads3</italic>
###xml 3445 3450 3316 3321 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Fads3</italic></td>
###xml 3450 3473 3321 3344 <td xmlns:xlink="http://www.w3.org/1999/xlink">fatty acid desaturase 3</td>
###xml 3473 3477 3344 3348 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.06</td>
###xml 3477 3477 3348 3348 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3445 3477 3316 3348 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Fads3</italic></td><td>fatty acid desaturase 3</td><td>2.06</td><td/></tr>
###xml 3477 3481 3348 3352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lipe</italic>
###xml 3477 3481 3348 3352 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Lipe</italic></td>
###xml 3481 3506 3352 3377 <td xmlns:xlink="http://www.w3.org/1999/xlink">lipase, hormone sensitive</td>
###xml 3506 3510 3377 3381 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.96</td>
###xml 3510 3514 3381 3385 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.66</td>
###xml 3477 3514 3348 3385 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Lipe</italic></td><td>lipase, hormone sensitive</td><td>1.96</td><td>1.66</td></tr>
###xml 3514 3518 3385 3389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lrp2</italic>
###xml 3514 3518 3385 3389 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Lrp2</italic></td>
###xml 3518 3568 3389 3439 <td xmlns:xlink="http://www.w3.org/1999/xlink">low density lipoprotein receptor-related protein 2</td>
###xml 3568 3572 3439 3443 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.91</td>
###xml 3572 3572 3443 3443 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3514 3572 3385 3443 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Lrp2</italic></td><td>low density lipoprotein receptor-related protein 2</td><td>1.91</td><td/></tr>
###xml 3572 3577 3443 3448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fabp5</italic>
###xml 3572 3577 3443 3448 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Fabp5</italic></td>
###xml 3577 3616 3448 3487 <td xmlns:xlink="http://www.w3.org/1999/xlink">fatty acid binding protein 5, epidermal</td>
###xml 3616 3620 3487 3491 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.87</td>
###xml 3620 3620 3491 3491 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3572 3620 3443 3491 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Fabp5</italic></td><td>fatty acid binding protein 5, epidermal</td><td>1.87</td><td/></tr>
###xml 3620 3625 3491 3496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dgat1</italic>
###xml 3620 3625 3491 3496 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Dgat1</italic></td>
###xml 3625 3655 3496 3526 <td xmlns:xlink="http://www.w3.org/1999/xlink">diacylglycerol acyltransferase</td>
###xml 3655 3659 3526 3530 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.87</td>
###xml 3659 3659 3530 3530 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3620 3659 3491 3530 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Dgat1</italic></td><td>diacylglycerol acyltransferase</td><td>1.87</td><td/></tr>
###xml 3659 3664 3530 3535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Decr1</italic>
###xml 3659 3664 3530 3535 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Decr1</italic></td>
###xml 3664 3706 3535 3577 <td xmlns:xlink="http://www.w3.org/1999/xlink">2,4-dienoyl CoA reductase 1, mitochondrial</td>
###xml 3706 3710 3577 3581 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.85</td>
###xml 3710 3710 3581 3581 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3659 3710 3530 3581 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Decr1</italic></td><td>2,4-dienoyl CoA reductase 1, mitochondrial</td><td>1.85</td><td/></tr>
###xml 3710 3717 3581 3588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Slc27a1</italic>
###xml 3710 3717 3581 3588 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Slc27a1</italic></td>
###xml 3717 3776 3588 3647 <td xmlns:xlink="http://www.w3.org/1999/xlink">solute carrier family 27 (fatty acid transporter), member 1</td>
###xml 3776 3780 3647 3651 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.85</td>
###xml 3780 3780 3651 3651 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3710 3780 3581 3651 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Slc27a1</italic></td><td>solute carrier family 27 (fatty acid transporter), member 1</td><td>1.85</td><td/></tr>
###xml 3780 3784 3651 3655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Phyh</italic>
###xml 3780 3784 3651 3655 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Phyh</italic></td>
###xml 3784 3808 3655 3679 <td xmlns:xlink="http://www.w3.org/1999/xlink">phytanol-CoA hydroxylase</td>
###xml 3808 3812 3679 3683 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.77</td>
###xml 3812 3812 3683 3683 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3780 3812 3651 3683 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Phyh</italic></td><td>phytanol-CoA hydroxylase</td><td>1.77</td><td/></tr>
###xml 3812 3819 3683 3690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dgat2/1</italic>
###xml 3812 3819 3683 3690 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Dgat2/1</italic></td>
###xml 3819 3860 3690 3731 <td xmlns:xlink="http://www.w3.org/1999/xlink">diacylglycerol O-acyltransferase 2-like 1</td>
###xml 3860 3864 3731 3735 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.75</td>
###xml 3864 3864 3735 3735 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3812 3864 3683 3735 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Dgat2/1</italic></td><td>diacylglycerol O-acyltransferase 2-like 1</td><td>1.75</td><td/></tr>
###xml 3864 3871 3735 3742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppargc1</italic>
###xml 3864 3871 3735 3742 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Ppargc1</italic></td>
###xml 3871 3936 3742 3807 <td xmlns:xlink="http://www.w3.org/1999/xlink">peroxisome proliferative activated receptor, gamma, coactivator 1</td>
###xml 3936 3940 3807 3811 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.74</td>
###xml 3940 3944 3811 3815 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.97</td>
###xml 3864 3944 3735 3815 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>Ppargc1</italic></td><td>peroxisome proliferative activated receptor, gamma, coactivator 1</td><td>1.74</td><td>1.97</td></tr>
###xml 2451 3944 2322 3815 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="4">Glucose metabolism</td></tr><tr><td><italic>Gys2</italic></td><td>glycogen synthase 2</td><td>13.27</td><td>9.28</td></tr><tr><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.99</td><td/></tr><tr><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.64</td><td/></tr><tr><td><italic>Gys3</italic></td><td>glycogen synthase 3, brain</td><td>2.25</td><td/></tr><tr><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>2.19</td><td/></tr><tr><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.16</td><td>1.56</td></tr><tr><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.04</td><td>1.56</td></tr><tr><td><italic>PFK-2</italic></td><td>6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase</td><td>2.01</td><td/></tr><tr><td><italic>Gdc1</italic></td><td>glycerol phosphate dehydrogenase 1, cytoplasmic adult</td><td>1.93</td><td/></tr><tr><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>1.91</td><td/></tr><tr><td><italic>Gdc1</italic></td><td>glycerolphosphate dehydrogenase 1, cytoplasmicadult</td><td>1.84</td><td/></tr><tr><td><italic>Pygl</italic></td><td>liver glycogen phosphorylase</td><td>1.71</td><td/></tr><tr><td colspan="4">Lipid metabolism</td></tr><tr><td><italic>Pparg</italic></td><td>peroxisome proliferator activator receptor gamma</td><td>2.99</td><td>3.63</td></tr><tr><td><italic>C5D</italic></td><td>sterol-C5-desaturase</td><td>2.85</td><td/></tr><tr><td><italic>Lrp1</italic></td><td>low density lipoprotein receptor-related protein 1</td><td>2.22</td><td/></tr><tr><td><italic>Cd36</italic></td><td>CD36 antigen</td><td>2.20</td><td>3.09]</td></tr><tr><td><italic>Fads3</italic></td><td>fatty acid desaturase 3</td><td>2.06</td><td/></tr><tr><td><italic>Lipe</italic></td><td>lipase, hormone sensitive</td><td>1.96</td><td>1.66</td></tr><tr><td><italic>Lrp2</italic></td><td>low density lipoprotein receptor-related protein 2</td><td>1.91</td><td/></tr><tr><td><italic>Fabp5</italic></td><td>fatty acid binding protein 5, epidermal</td><td>1.87</td><td/></tr><tr><td><italic>Dgat1</italic></td><td>diacylglycerol acyltransferase</td><td>1.87</td><td/></tr><tr><td><italic>Decr1</italic></td><td>2,4-dienoyl CoA reductase 1, mitochondrial</td><td>1.85</td><td/></tr><tr><td><italic>Slc27a1</italic></td><td>solute carrier family 27 (fatty acid transporter), member 1</td><td>1.85</td><td/></tr><tr><td><italic>Phyh</italic></td><td>phytanol-CoA hydroxylase</td><td>1.77</td><td/></tr><tr><td><italic>Dgat2/1</italic></td><td>diacylglycerol O-acyltransferase 2-like 1</td><td>1.75</td><td/></tr><tr><td><italic>Ppargc1</italic></td><td>peroxisome proliferative activated receptor, gamma, coactivator 1</td><td>1.74</td><td>1.97</td></tr></tbody>
###xml 2410 3944 2281 3815 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Product</th><th>Fold decrease Micro-array</th><th>Q-PCR</th></tr></thead><tbody><tr><td colspan="4">Glucose metabolism</td></tr><tr><td><italic>Gys2</italic></td><td>glycogen synthase 2</td><td>13.27</td><td>9.28</td></tr><tr><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.99</td><td/></tr><tr><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.64</td><td/></tr><tr><td><italic>Gys3</italic></td><td>glycogen synthase 3, brain</td><td>2.25</td><td/></tr><tr><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>2.19</td><td/></tr><tr><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.16</td><td>1.56</td></tr><tr><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.04</td><td>1.56</td></tr><tr><td><italic>PFK-2</italic></td><td>6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase</td><td>2.01</td><td/></tr><tr><td><italic>Gdc1</italic></td><td>glycerol phosphate dehydrogenase 1, cytoplasmic adult</td><td>1.93</td><td/></tr><tr><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>1.91</td><td/></tr><tr><td><italic>Gdc1</italic></td><td>glycerolphosphate dehydrogenase 1, cytoplasmicadult</td><td>1.84</td><td/></tr><tr><td><italic>Pygl</italic></td><td>liver glycogen phosphorylase</td><td>1.71</td><td/></tr><tr><td colspan="4">Lipid metabolism</td></tr><tr><td><italic>Pparg</italic></td><td>peroxisome proliferator activator receptor gamma</td><td>2.99</td><td>3.63</td></tr><tr><td><italic>C5D</italic></td><td>sterol-C5-desaturase</td><td>2.85</td><td/></tr><tr><td><italic>Lrp1</italic></td><td>low density lipoprotein receptor-related protein 1</td><td>2.22</td><td/></tr><tr><td><italic>Cd36</italic></td><td>CD36 antigen</td><td>2.20</td><td>3.09]</td></tr><tr><td><italic>Fads3</italic></td><td>fatty acid desaturase 3</td><td>2.06</td><td/></tr><tr><td><italic>Lipe</italic></td><td>lipase, hormone sensitive</td><td>1.96</td><td>1.66</td></tr><tr><td><italic>Lrp2</italic></td><td>low density lipoprotein receptor-related protein 2</td><td>1.91</td><td/></tr><tr><td><italic>Fabp5</italic></td><td>fatty acid binding protein 5, epidermal</td><td>1.87</td><td/></tr><tr><td><italic>Dgat1</italic></td><td>diacylglycerol acyltransferase</td><td>1.87</td><td/></tr><tr><td><italic>Decr1</italic></td><td>2,4-dienoyl CoA reductase 1, mitochondrial</td><td>1.85</td><td/></tr><tr><td><italic>Slc27a1</italic></td><td>solute carrier family 27 (fatty acid transporter), member 1</td><td>1.85</td><td/></tr><tr><td><italic>Phyh</italic></td><td>phytanol-CoA hydroxylase</td><td>1.77</td><td/></tr><tr><td><italic>Dgat2/1</italic></td><td>diacylglycerol O-acyltransferase 2-like 1</td><td>1.75</td><td/></tr><tr><td><italic>Ppargc1</italic></td><td>peroxisome proliferative activated receptor, gamma, coactivator 1</td><td>1.74</td><td>1.97</td></tr></tbody></table>
###xml 2252 3944 2130 3815 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p textid="28">Genes involved in glucose and lipid metabolism that were differentially expressed between white adipose tissue of wild-type and PPAR&#946;/&#948;<sup>-/-</sup> mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Product</th><th>Fold decrease Micro-array</th><th>Q-PCR</th></tr></thead><tbody><tr><td colspan="4">Glucose metabolism</td></tr><tr><td><italic>Gys2</italic></td><td>glycogen synthase 2</td><td>13.27</td><td>9.28</td></tr><tr><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.99</td><td/></tr><tr><td><italic>Pik3r1</italic></td><td>phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)</td><td>2.64</td><td/></tr><tr><td><italic>Gys3</italic></td><td>glycogen synthase 3, brain</td><td>2.25</td><td/></tr><tr><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>2.19</td><td/></tr><tr><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.16</td><td>1.56</td></tr><tr><td><italic>Slc2a4</italic></td><td>solute carrier family 2 (facilitated glucose transporter), member 4</td><td>2.04</td><td>1.56</td></tr><tr><td><italic>PFK-2</italic></td><td>6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase</td><td>2.01</td><td/></tr><tr><td><italic>Gdc1</italic></td><td>glycerol phosphate dehydrogenase 1, cytoplasmic adult</td><td>1.93</td><td/></tr><tr><td><italic>Ppp1r3c</italic></td><td>protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen</td><td>1.91</td><td/></tr><tr><td><italic>Gdc1</italic></td><td>glycerolphosphate dehydrogenase 1, cytoplasmicadult</td><td>1.84</td><td/></tr><tr><td><italic>Pygl</italic></td><td>liver glycogen phosphorylase</td><td>1.71</td><td/></tr><tr><td colspan="4">Lipid metabolism</td></tr><tr><td><italic>Pparg</italic></td><td>peroxisome proliferator activator receptor gamma</td><td>2.99</td><td>3.63</td></tr><tr><td><italic>C5D</italic></td><td>sterol-C5-desaturase</td><td>2.85</td><td/></tr><tr><td><italic>Lrp1</italic></td><td>low density lipoprotein receptor-related protein 1</td><td>2.22</td><td/></tr><tr><td><italic>Cd36</italic></td><td>CD36 antigen</td><td>2.20</td><td>3.09]</td></tr><tr><td><italic>Fads3</italic></td><td>fatty acid desaturase 3</td><td>2.06</td><td/></tr><tr><td><italic>Lipe</italic></td><td>lipase, hormone sensitive</td><td>1.96</td><td>1.66</td></tr><tr><td><italic>Lrp2</italic></td><td>low density lipoprotein receptor-related protein 2</td><td>1.91</td><td/></tr><tr><td><italic>Fabp5</italic></td><td>fatty acid binding protein 5, epidermal</td><td>1.87</td><td/></tr><tr><td><italic>Dgat1</italic></td><td>diacylglycerol acyltransferase</td><td>1.87</td><td/></tr><tr><td><italic>Decr1</italic></td><td>2,4-dienoyl CoA reductase 1, mitochondrial</td><td>1.85</td><td/></tr><tr><td><italic>Slc27a1</italic></td><td>solute carrier family 27 (fatty acid transporter), member 1</td><td>1.85</td><td/></tr><tr><td><italic>Phyh</italic></td><td>phytanol-CoA hydroxylase</td><td>1.77</td><td/></tr><tr><td><italic>Dgat2/1</italic></td><td>diacylglycerol O-acyltransferase 2-like 1</td><td>1.75</td><td/></tr><tr><td><italic>Ppargc1</italic></td><td>peroxisome proliferative activated receptor, gamma, coactivator 1</td><td>1.74</td><td>1.97</td></tr></tbody></table></table-wrap>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:10090">mice</span>
###xml 919 923 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1541 1545 <span type="species:ncbi:10090">mice</span>
###xml 1560 1564 <span type="species:ncbi:10090">mice</span>
###xml 1582 1586 <span type="species:ncbi:10090">mice</span>
###xml 2405 2409 <span type="species:ncbi:10090">mice</span>
Our initial aim was to identify novel putative target genes of PPARbeta/delta in WAT. Accordingly, we compared gene expression in WAT of wild-type versus PPARbeta/delta-/- mice using Affymetrix micro-array analysis. The expression of several genes involved in glucose and lipid metabolism was down-regulated in PPARbeta/delta-/-mice, including PPARgamma, PGC-lalpha, and GLUT4, which was confirmed for several genes by real-time quantitative PCR (qPCR) (Table 1). Expression of Gys-2 was most significantly down-regulated in PPARbeta/delta-/-mice, and therefore Gys-2 was selected for more detailed investigation. Q-PCR confirmed the marked down-regulation of Gys-2 mRNA in WAT of PPARbeta/delta-/- mice (Fig. la). Furthermore, expression of Gys-2 also appeared to be down-regulated in WAT of PPARgamma+/- and PPARalpha-/- mice, although the former result did not achieve statistical significance. In PPARbeta/delta-/- mice, the decrease in Gys-2 mRNA was paralleled by a significant down-regulation of PPARalpha and PPARgamma expression, while in PPARalpha-/- mice expression of PPARbeta/delta was significantly down-regulated (Fig. lb). These data show that PPARs are crucial for maintaining Gys-2 expression in fat, although it is difficult to ascertain which PPAR isotype is the main regulator of Gys-2 expression in WAT. Figure 1Expression of Glycogen synthase 2 (Gys-2) in white adipose tissue (WAT) is regulated by peroxisome proliferator-activated receptors (PPARs). Expression of Gys-2 (a) and PPARs (b) in WAT of PPARbeta/delta-/- mice, PPARgamma+/- mice, and PPARalpha-/-mice, as determined by qPCR. The effects of PPAR deletion were evaluated by Student's Mest (* p<0.05; ** p<0.01). Error bars represent SEM (n=5). (c) Differentiated 3T3-L1 adipocytes were treated with the synthetic PPARgamma agonists rosiglitazone or ciglitazone, or the PPARbeta/delta agonist L165041 for 24 h. Expression of Gys-2 was determined by qPCR. Expression of cells treated with vehicle (DMSO) was set at 1. Data shown are representative results from three independent experiments, (d) Gys protein expression was analyzed in lysates from 3T3-L1 adipocytes treated with either PPARbeta/delta (L165041, 2.5 microM) or PPARgamma (rosiglitazone, 1 microM) agonist.Table 1Genes involved in glucose and lipid metabolism that were differentially expressed between white adipose tissue of wild-type and PPARbeta/delta-/- mice.GeneProductFold decrease Micro-arrayQ-PCRGlucose metabolismGys2glycogen synthase 213.279.28Pik3r1phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)2.99Pik3r1phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)2.64Gys3glycogen synthase 3, brain2.25Ppp1r3cprotein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen2.19Slc2a4solute carrier family 2 (facilitated glucose transporter), member 42.161.56Slc2a4solute carrier family 2 (facilitated glucose transporter), member 42.041.56PFK-26-phosphofructo-2-kinase/fructose-2,6-bisphosphatase2.01Gdc1glycerol phosphate dehydrogenase 1, cytoplasmic adult1.93Ppp1r3cprotein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen1.91Gdc1glycerolphosphate dehydrogenase 1, cytoplasmicadult1.84Pyglliver glycogen phosphorylase1.71Lipid metabolismPpargperoxisome proliferator activator receptor gamma2.993.63C5Dsterol-C5-desaturase2.85Lrp1low density lipoprotein receptor-related protein 12.22Cd36CD36 antigen2.203.09]Fads3fatty acid desaturase 32.06Lipelipase, hormone sensitive1.961.66Lrp2low density lipoprotein receptor-related protein 21.91Fabp5fatty acid binding protein 5, epidermal1.87Dgat1diacylglycerol acyltransferase1.87Decr12,4-dienoyl CoA reductase 1, mitochondrial1.85Slc27a1solute carrier family 27 (fatty acid transporter), member 11.85Phyhphytanol-CoA hydroxylase1.77Dgat2/1diacylglycerol O-acyltransferase 2-like 11.75Ppargc1peroxisome proliferative activated receptor, gamma, coactivator 11.741.97
###end p 26
###begin p 27
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 203 206 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 222 225 211 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 245 248 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 342 343 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 353 354 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 388 389 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 395 396 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 741 742 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
Expression of Glycogen synthase 2 (Gys-2) in white adipose tissue (WAT) is regulated by peroxisome proliferator-activated receptors (PPARs). Expression of Gys-2 (a) and PPARs (b) in WAT of PPARbeta/delta-/- mice, PPARgamma+/- mice, and PPARalpha-/-mice, as determined by qPCR. The effects of PPAR deletion were evaluated by Student's Mest (* p<0.05; ** p<0.01). Error bars represent SEM (n=5). (c) Differentiated 3T3-L1 adipocytes were treated with the synthetic PPARgamma agonists rosiglitazone or ciglitazone, or the PPARbeta/delta agonist L165041 for 24 h. Expression of Gys-2 was determined by qPCR. Expression of cells treated with vehicle (DMSO) was set at 1. Data shown are representative results from three independent experiments, (d) Gys protein expression was analyzed in lysates from 3T3-L1 adipocytes treated with either PPARbeta/delta (L165041, 2.5 microM) or PPARgamma (rosiglitazone, 1 microM) agonist.
###end p 27
###begin p 28
###xml 142 145 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
Genes involved in glucose and lipid metabolism that were differentially expressed between white adipose tissue of wild-type and PPARbeta/delta-/- mice.
###end p 28
###begin p 29
###xml 347 349 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1c</xref>
###xml 405 407 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1d</xref>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
To investigate whether expression of Gys-2 in adipocytes is under direct control of PPARs, the effect of PPAR ligands on Gys-2 mRNA was studied in differentiated mouse 3T3-L1 adipocytes. It was observed that the PPARbeta/delta agonist L165041, and the PPARgamma agonists ciglitazone and rosiglitazone significantly induced Gys-2 mRNA levels (Fig. 1c). This effect was confirmed at the protein level (Fig. 1d). Thus, Gys-2 may represent a direct target gene of PPARgamma and PPARbeta/delta in adipocytes.
###end p 29
###begin p 30
###xml 0 43 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PPAR&#945; governs Gys-2 hepatic expression.</bold>
###xml 221 223 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 225 227 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 284 285 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 365 367 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 583 585 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3a</xref>
###xml 985 987 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3b</xref>
###xml 1094 1096 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3b</xref>
###xml 1212 1214 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3c</xref>
###xml 1312 1320 1260 1268 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 2</label>
###xml 1422 1423 1366 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1527 1528 1467 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1320 1686 1268 1622 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Staining for hepatic glycogen is higher in refed wild-type mice compared to refed PPAR&#945;-/- mice, (<italic>a</italic>) Representative hematoxylin and eosin staining of liver from two wild-type and two PPAR&#945;-/- mice, (<italic>b</italic>) Representative PAS staining of liver from two wild-type and two PPAR&#945;-/- mice. Mice were fasted for 24 h followed by refeeding for 7 h before sacrifice.</p>
###xml 1320 1686 1268 1622 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Staining for hepatic glycogen is higher in refed wild-type mice compared to refed PPAR&#945;-/- mice, (<italic>a</italic>) Representative hematoxylin and eosin staining of liver from two wild-type and two PPAR&#945;-/- mice, (<italic>b</italic>) Representative PAS staining of liver from two wild-type and two PPAR&#945;-/- mice. Mice were fasted for 24 h followed by refeeding for 7 h before sacrifice.</p></caption>
###xml 1686 1686 1622 1622 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig2" id="MO2"/>
###xml 1312 1686 1260 1622 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Figure 2</label><caption><p textid="31">Staining for hepatic glycogen is higher in refed wild-type mice compared to refed PPAR&#945;-/- mice, (<italic>a</italic>) Representative hematoxylin and eosin staining of liver from two wild-type and two PPAR&#945;-/- mice, (<italic>b</italic>) Representative PAS staining of liver from two wild-type and two PPAR&#945;-/- mice. Mice were fasted for 24 h followed by refeeding for 7 h before sacrifice.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig2" id="MO2"/></fig>
###xml 1686 1694 1622 1630 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 3</label>
###xml 1742 1743 1674 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 2058 2059 1982 1983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2298 2299 2214 2215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2366 2367 2282 2283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2376 2377 2292 2293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2631 2632 2543 2544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1694 2665 1630 2577 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">PPAR&#945; governs hepatic expression of Gys-2. (<italic>a</italic>) Relative expression of Gys-2 in fed, fasted and refed wild-type and PPAR&#945;-/- mice, as determined by qPCR. Mice were fasted for 0,6, 12 or 24 h, with refeeding for 7 h following 24 h fasting. Significant differences between wild-type and PPAR&#945;-/- mice were observed in the 24-h fasted and the refed state (<italic>b</italic>) Relative expression of Gys-2 in freshly isolated wild-type and PPAR&#945;-/- hepatocytes treated for 24 h with vehicle (DMSO) or Wy14643 (10 &#181;M), as determined by qPCR. Significant effects were observed by two-way ANOVA for genotype (<italic>p</italic>&lt;0.001), and for the interaction between the genotype and Wy14643 (<italic>p</italic>&lt;0.05). (<italic>c</italic>) Relative expression of Gys-2 in freshly isolated rat hepatocytes which were treated for 24 h with either vehicle (DMSO), Wy14643 (50 uM) or fenofibrate (50 &#181;M). The effects of Wy14643 and fenofibrate were statistically significant (Student&#8217;s Mest: <italic>p</italic>&lt;0.01). Error bars represent SEM.</p>
###xml 1694 2665 1630 2577 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">PPAR&#945; governs hepatic expression of Gys-2. (<italic>a</italic>) Relative expression of Gys-2 in fed, fasted and refed wild-type and PPAR&#945;-/- mice, as determined by qPCR. Mice were fasted for 0,6, 12 or 24 h, with refeeding for 7 h following 24 h fasting. Significant differences between wild-type and PPAR&#945;-/- mice were observed in the 24-h fasted and the refed state (<italic>b</italic>) Relative expression of Gys-2 in freshly isolated wild-type and PPAR&#945;-/- hepatocytes treated for 24 h with vehicle (DMSO) or Wy14643 (10 &#181;M), as determined by qPCR. Significant effects were observed by two-way ANOVA for genotype (<italic>p</italic>&lt;0.001), and for the interaction between the genotype and Wy14643 (<italic>p</italic>&lt;0.05). (<italic>c</italic>) Relative expression of Gys-2 in freshly isolated rat hepatocytes which were treated for 24 h with either vehicle (DMSO), Wy14643 (50 uM) or fenofibrate (50 &#181;M). The effects of Wy14643 and fenofibrate were statistically significant (Student&#8217;s Mest: <italic>p</italic>&lt;0.01). Error bars represent SEM.</p></caption>
###xml 2665 2665 2577 2577 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig3" id="MO3"/>
###xml 1686 2665 1622 2577 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Figure 3</label><caption><p textid="32">PPAR&#945; governs hepatic expression of Gys-2. (<italic>a</italic>) Relative expression of Gys-2 in fed, fasted and refed wild-type and PPAR&#945;-/- mice, as determined by qPCR. Mice were fasted for 0,6, 12 or 24 h, with refeeding for 7 h following 24 h fasting. Significant differences between wild-type and PPAR&#945;-/- mice were observed in the 24-h fasted and the refed state (<italic>b</italic>) Relative expression of Gys-2 in freshly isolated wild-type and PPAR&#945;-/- hepatocytes treated for 24 h with vehicle (DMSO) or Wy14643 (10 &#181;M), as determined by qPCR. Significant effects were observed by two-way ANOVA for genotype (<italic>p</italic>&lt;0.001), and for the interaction between the genotype and Wy14643 (<italic>p</italic>&lt;0.05). (<italic>c</italic>) Relative expression of Gys-2 in freshly isolated rat hepatocytes which were treated for 24 h with either vehicle (DMSO), Wy14643 (50 uM) or fenofibrate (50 &#181;M). The effects of Wy14643 and fenofibrate were statistically significant (Student&#8217;s Mest: <italic>p</italic>&lt;0.01). Error bars represent SEM.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig3" id="MO3"/></fig>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
###xml 1182 1185 <span type="species:ncbi:10116">rat</span>
###xml 1379 1383 <span type="species:ncbi:10090">mice</span>
###xml 1415 1419 <span type="species:ncbi:10090">mice</span>
###xml 1520 1524 <span type="species:ncbi:10090">mice</span>
###xml 1607 1611 <span type="species:ncbi:10090">mice</span>
###xml 1613 1617 <span type="species:ncbi:10090">Mice</span>
###xml 1826 1830 <span type="species:ncbi:10090">mice</span>
###xml 1855 1859 <span type="species:ncbi:10090">Mice</span>
###xml 1999 2003 <span type="species:ncbi:10090">mice</span>
###xml 2428 2431 <span type="species:ncbi:10116">rat</span>
PPARalpha governs Gys-2 hepatic expression. A link between PPARs and glycogen has been previously made. It was observed that liver glycogen levels were reduced in refed PPARalpha-/- mice compared to refed wild-type mice [30, 31], which we confirmed using histochemical staining (Fig. 2). Furthermore, hepatic expression of Gys-2 was decreased in PPARalpha-/- mice [32]. Expression of Gys-2 is highest in liver, followed by WAT (our unpublished data). We confirm that hepatic Gys-2 mRNA is markedly reduced in PPARalpha-/- mice; however, only in the 24-h fasted and refed state (Fig. 3a). To further examine the role of PPARalpha in Gys-2 expression, primary hepatocytes from wild-type and PPARalpha-/- mice were treated with the synthetic PPARalpha agonist Wy14643, allowing for a direct evaluation of the effect of PPARalpha activation on Gys-2 expression. Basal expression of Gys-2 was about fourfold reduced in PPARalpha-/- hepatocytes, indicating a requirement for PPARalpha (Fig. 3b). Furthermore, Wy14643 stimulated Gys-2 expression in wild-type but not in PPARalpha-/- hepatocytes (Fig. 3b). Induction of Gys-2 expression by synthetic PPARalpha agonists was also observed in rat primary hepatocytes (Fig. 3c). Together, these data suggest a direct role of PPARalpha in governing hepatic Gys-2 expression. Figure 2Staining for hepatic glycogen is higher in refed wild-type mice compared to refed PPARalpha-/- mice, (a) Representative hematoxylin and eosin staining of liver from two wild-type and two PPARalpha-/- mice, (b) Representative PAS staining of liver from two wild-type and two PPARalpha-/- mice. Mice were fasted for 24 h followed by refeeding for 7 h before sacrifice.Figure 3PPARalpha governs hepatic expression of Gys-2. (a) Relative expression of Gys-2 in fed, fasted and refed wild-type and PPARalpha-/- mice, as determined by qPCR. Mice were fasted for 0,6, 12 or 24 h, with refeeding for 7 h following 24 h fasting. Significant differences between wild-type and PPARalpha-/- mice were observed in the 24-h fasted and the refed state (b) Relative expression of Gys-2 in freshly isolated wild-type and PPARalpha-/- hepatocytes treated for 24 h with vehicle (DMSO) or Wy14643 (10 microM), as determined by qPCR. Significant effects were observed by two-way ANOVA for genotype (p<0.001), and for the interaction between the genotype and Wy14643 (p<0.05). (c) Relative expression of Gys-2 in freshly isolated rat hepatocytes which were treated for 24 h with either vehicle (DMSO), Wy14643 (50 uM) or fenofibrate (50 microM). The effects of Wy14643 and fenofibrate were statistically significant (Student's Mest: p<0.01). Error bars represent SEM.
###end p 30
###begin p 31
###xml 102 103 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 207 208 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:10090">Mice</span>
Staining for hepatic glycogen is higher in refed wild-type mice compared to refed PPARalpha-/- mice, (a) Representative hematoxylin and eosin staining of liver from two wild-type and two PPARalpha-/- mice, (b) Representative PAS staining of liver from two wild-type and two PPARalpha-/- mice. Mice were fasted for 24 h followed by refeeding for 7 h before sacrifice.
###end p 31
###begin p 32
###xml 48 49 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 364 365 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 604 605 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 672 673 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 682 683 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 937 938 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">Mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 734 737 <span type="species:ncbi:10116">rat</span>
PPARalpha governs hepatic expression of Gys-2. (a) Relative expression of Gys-2 in fed, fasted and refed wild-type and PPARalpha-/- mice, as determined by qPCR. Mice were fasted for 0,6, 12 or 24 h, with refeeding for 7 h following 24 h fasting. Significant differences between wild-type and PPARalpha-/- mice were observed in the 24-h fasted and the refed state (b) Relative expression of Gys-2 in freshly isolated wild-type and PPARalpha-/- hepatocytes treated for 24 h with vehicle (DMSO) or Wy14643 (10 microM), as determined by qPCR. Significant effects were observed by two-way ANOVA for genotype (p<0.001), and for the interaction between the genotype and Wy14643 (p<0.05). (c) Relative expression of Gys-2 in freshly isolated rat hepatocytes which were treated for 24 h with either vehicle (DMSO), Wy14643 (50 uM) or fenofibrate (50 microM). The effects of Wy14643 and fenofibrate were statistically significant (Student's Mest: p<0.01). Error bars represent SEM.
###end p 32
###begin p 33
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of a putative PPRE in the proximal promoter of the mouse Gys-2 gene</bold>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4a</xref>
###xml 657 665 657 665 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 4</label>
###xml 754 755 754 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 868 869 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1032 1033 1032 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1527 1528 1508 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1551 1552 1524 1525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 1764 1766 1737 1739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI</italic>
###xml 1785 1789 1758 1762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cntl</italic>
###xml 1817 1818 1790 1791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 665 1915 665 1888 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">The DR-1 present in the Gys-2 promoter does not mediate PPAR-dependent transactivation. (<italic>a</italic>) Alignment of the consensus PPRE sequence with the sequence of rat and mouse Gys-2 DR-lprom and Gys-2 DR-lint. (<italic>b</italic>) HepG2 cells were transfected with a reporter vector containing a 553-nucleotide fragment of the proximal mouse Gys-2 promoter gene and PPAR expression vectors, (<italic>c</italic>) HepG2 cells were transfected with a SV40 reporter vector containing an isolated 156-nucleotide fragment surrounding DR-lprom of the proximal mouse Gys-2 promoter gene and PPAR expression vectors. Luciferase and &#946;-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 &#181;M Wy14643, 5 &#181;M L-165041 and 10 &#181;M of rosiglitazone. Error bars represent SEM. Chromatin immunoprecipitation of DR-lprom using antibodies against mPPAR&#947; (<italic>d</italic>) or mPPAR&#948;/&#948; (<italic>e</italic>). The gene sequence spanning DR-lprom and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes. Preimmune serum was used as a control. <italic>PI</italic>, preimmune serum, <italic>Cntl</italic>, random control sequence. (<italic>f</italic>) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.</p>
###xml 665 1915 665 1888 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">The DR-1 present in the Gys-2 promoter does not mediate PPAR-dependent transactivation. (<italic>a</italic>) Alignment of the consensus PPRE sequence with the sequence of rat and mouse Gys-2 DR-lprom and Gys-2 DR-lint. (<italic>b</italic>) HepG2 cells were transfected with a reporter vector containing a 553-nucleotide fragment of the proximal mouse Gys-2 promoter gene and PPAR expression vectors, (<italic>c</italic>) HepG2 cells were transfected with a SV40 reporter vector containing an isolated 156-nucleotide fragment surrounding DR-lprom of the proximal mouse Gys-2 promoter gene and PPAR expression vectors. Luciferase and &#946;-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 &#181;M Wy14643, 5 &#181;M L-165041 and 10 &#181;M of rosiglitazone. Error bars represent SEM. Chromatin immunoprecipitation of DR-lprom using antibodies against mPPAR&#947; (<italic>d</italic>) or mPPAR&#948;/&#948; (<italic>e</italic>). The gene sequence spanning DR-lprom and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes. Preimmune serum was used as a control. <italic>PI</italic>, preimmune serum, <italic>Cntl</italic>, random control sequence. (<italic>f</italic>) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.</p></caption>
###xml 1915 1915 1888 1888 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig4" id="MO4"/>
###xml 657 1915 657 1888 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Figure 4</label><caption><p textid="34">The DR-1 present in the Gys-2 promoter does not mediate PPAR-dependent transactivation. (<italic>a</italic>) Alignment of the consensus PPRE sequence with the sequence of rat and mouse Gys-2 DR-lprom and Gys-2 DR-lint. (<italic>b</italic>) HepG2 cells were transfected with a reporter vector containing a 553-nucleotide fragment of the proximal mouse Gys-2 promoter gene and PPAR expression vectors, (<italic>c</italic>) HepG2 cells were transfected with a SV40 reporter vector containing an isolated 156-nucleotide fragment surrounding DR-lprom of the proximal mouse Gys-2 promoter gene and PPAR expression vectors. Luciferase and &#946;-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 &#181;M Wy14643, 5 &#181;M L-165041 and 10 &#181;M of rosiglitazone. Error bars represent SEM. Chromatin immunoprecipitation of DR-lprom using antibodies against mPPAR&#947; (<italic>d</italic>) or mPPAR&#948;/&#948; (<italic>e</italic>). The gene sequence spanning DR-lprom and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes. Preimmune serum was used as a control. <italic>PI</italic>, preimmune serum, <italic>Cntl</italic>, random control sequence. (<italic>f</italic>) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig4" id="MO4"/></fig>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 642 647 <span type="species:ncbi:10090">mouse</span>
###xml 652 655 <span type="species:ncbi:10116">rat</span>
###xml 819 822 <span type="species:ncbi:10116">rat</span>
###xml 827 832 <span type="species:ncbi:10090">mouse</span>
###xml 976 981 <span type="species:ncbi:10090">mouse</span>
###xml 1071 1075 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1176 1181 <span type="species:ncbi:10090">mouse</span>
Identification of a putative PPRE in the proximal promoter of the mouse Gys-2 gene. To determine what genomic region could be responsible for the PPAR-induced up-regulation of Gys-2 mRNA, the mouse Gys-2 gene was scanned for potential PPREs (NUBIScan algorithm and Hidden Markov Model framework) [33, 34]. A Direct Repeat-1 motif (DR-lprom) was localized to the proximal Gys-2 gene promoter, about 169 bp upstream from the transcription start site. With the exception of two nucleotides, DR-lprom is identical to the consensus sequence, suggesting that this sequence could serve as a functional PPRE (Fig. 4a). DR-lprom was conserved between mouse and rat. Figure 4The DR-1 present in the Gys-2 promoter does not mediate PPAR-dependent transactivation. (a) Alignment of the consensus PPRE sequence with the sequence of rat and mouse Gys-2 DR-lprom and Gys-2 DR-lint. (b) HepG2 cells were transfected with a reporter vector containing a 553-nucleotide fragment of the proximal mouse Gys-2 promoter gene and PPAR expression vectors, (c) HepG2 cells were transfected with a SV40 reporter vector containing an isolated 156-nucleotide fragment surrounding DR-lprom of the proximal mouse Gys-2 promoter gene and PPAR expression vectors. Luciferase and beta-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 microM Wy14643, 5 microM L-165041 and 10 microM of rosiglitazone. Error bars represent SEM. Chromatin immunoprecipitation of DR-lprom using antibodies against mPPARgamma (d) or mPPARdelta/delta (e). The gene sequence spanning DR-lprom and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes. Preimmune serum was used as a control. PI, preimmune serum, Cntl, random control sequence. (f) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.
###end p 33
###begin p 34
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 862 863 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 886 887 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 1099 1101 1072 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI</italic>
###xml 1120 1124 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cntl</italic>
###xml 1152 1153 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 154 157 <span type="species:ncbi:10116">rat</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 311 316 <span type="species:ncbi:10090">mouse</span>
###xml 406 410 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 511 516 <span type="species:ncbi:10090">mouse</span>
The DR-1 present in the Gys-2 promoter does not mediate PPAR-dependent transactivation. (a) Alignment of the consensus PPRE sequence with the sequence of rat and mouse Gys-2 DR-lprom and Gys-2 DR-lint. (b) HepG2 cells were transfected with a reporter vector containing a 553-nucleotide fragment of the proximal mouse Gys-2 promoter gene and PPAR expression vectors, (c) HepG2 cells were transfected with a SV40 reporter vector containing an isolated 156-nucleotide fragment surrounding DR-lprom of the proximal mouse Gys-2 promoter gene and PPAR expression vectors. Luciferase and beta-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 microM Wy14643, 5 microM L-165041 and 10 microM of rosiglitazone. Error bars represent SEM. Chromatin immunoprecipitation of DR-lprom using antibodies against mPPARgamma (d) or mPPARdelta/delta (e). The gene sequence spanning DR-lprom and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes. Preimmune serum was used as a control. PI, preimmune serum, Cntl, random control sequence. (f) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.
###end p 34
###begin p 35
###xml 513 515 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4b</xref>
###xml 763 765 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4c</xref>
###xml 1172 1174 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4d</xref>
###xml 1287 1289 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4e</xref>
###xml 1455 1462 1397 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
###xml 621 625 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
To examine whether the promoter region containing the putative PPRE is responsible for PPAR-dependent up-regulation of Gys-2 expression, a 553-nucleotide fragment of the mouse Gys-2 promoter gene was cloned in front of a luciferase reporter gene and transactivation studies were carried out in HepG2 cells. Surprisingly, co-transfection of PPARalpha or PPARgammal expression vectors in combination with PPAR agonists slightly decreased luciferase activity, while PPARbeta/delta activation had little effect (Fig. 4b). Transactivation assays performed with a small genomic fragment surrounding DR-lprom cloned in front of SV40-luciferase led to a similar overall PPAR-mediated repression for PPARalpha and PPARgammal, while PPARgamma/delta had little effect (Fig. 4c). Co-transfection of RXR or of different co-activators such as CBP and PGClalpha did not change this pattern (data not shown). Thus, the PPRE identified in the Gys-2 promoter probably does not mediate the effect of PPARs on Gys-2 expression. Nevertheless, ChIP experiments carried out in 3T3-L1 cells indicated that (1) PPARgamma was bound to DR-lprom in mature adipocytes, but not in pre-adipocytes (Fig. 4d), and (2) PPARbeta/delta was bound to DR-lprom in pre-adipocytes and, more strongly, in mature adipocytes (Fig. 4e). Thus, despite DR-lprom behaving poorly as a PPRE in classical transactivation assay, it binds both PPARgamma and PPARdelta/delta in adipocytes. This suggests that in vivo binding of PPARgamma and PPARdelta/delta to DR-lprom does not translate into transcriptional activation of the Gys-2 gene, and accordingly that activation of Gys-2 expression by PPARs may be mediated by another genomic region. It should be mentioned that ChIP did not reveal any binding of PPARalpha to DR-lprom in hepatocytes (data not shown).
###end p 35
###begin p 36
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4a</xref>
###xml 578 580 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5a</xref>
###xml 706 708 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5a</xref>
###xml 918 926 899 907 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 5</label>
###xml 1027 1028 1008 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1370 1371 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1535 1543 1501 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1691 1699 1642 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 926 1847 907 1794 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Gys-2 up-regulation by PPARs is mediated by a PPRE present in intron 1 of the Gys-2 gene (DR-lint). (<italic>a</italic>) HepG2 cells were transfected with a 314-nucleotide fragment of intron 1 of the mouse Gys-2 gene and PPAR expression vectors. Luciferase and &#946;-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 &#181;M Wy14643, 5 &#181;M L-165041 and 10 &#181;M rosiglitazone. Error bars represent SEM. (<italic>b</italic>) Binding of the PPAR/RXR heterodimers to DR-lint as determined by gel shift assays. A double-stranded response element containing Gys-2 DR-lint was incubated with <italic>in vitro</italic> transcribed/translated mPPAR&#945; protein (left panel), mPPAR&#946;/&#948; protein (middle panel) and mPPAR&#947;l protein (right panel) together with <italic>in vitro</italic> transcribed/translated hRXR&#945; protein. Fold excess of specific (malic enzyme PPRE) or nonspecific (ETS oligonucleotide) cold probe is indicated.</p>
###xml 926 1847 907 1794 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Gys-2 up-regulation by PPARs is mediated by a PPRE present in intron 1 of the Gys-2 gene (DR-lint). (<italic>a</italic>) HepG2 cells were transfected with a 314-nucleotide fragment of intron 1 of the mouse Gys-2 gene and PPAR expression vectors. Luciferase and &#946;-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 &#181;M Wy14643, 5 &#181;M L-165041 and 10 &#181;M rosiglitazone. Error bars represent SEM. (<italic>b</italic>) Binding of the PPAR/RXR heterodimers to DR-lint as determined by gel shift assays. A double-stranded response element containing Gys-2 DR-lint was incubated with <italic>in vitro</italic> transcribed/translated mPPAR&#945; protein (left panel), mPPAR&#946;/&#948; protein (middle panel) and mPPAR&#947;l protein (right panel) together with <italic>in vitro</italic> transcribed/translated hRXR&#945; protein. Fold excess of specific (malic enzyme PPRE) or nonspecific (ETS oligonucleotide) cold probe is indicated.</p></caption>
###xml 1847 1847 1794 1794 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig5" id="MO5"/>
###xml 918 1847 899 1794 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Figure 5</label><caption><p textid="37">Gys-2 up-regulation by PPARs is mediated by a PPRE present in intron 1 of the Gys-2 gene (DR-lint). (<italic>a</italic>) HepG2 cells were transfected with a 314-nucleotide fragment of intron 1 of the mouse Gys-2 gene and PPAR expression vectors. Luciferase and &#946;-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 &#181;M Wy14643, 5 &#181;M L-165041 and 10 &#181;M rosiglitazone. Error bars represent SEM. (<italic>b</italic>) Binding of the PPAR/RXR heterodimers to DR-lint as determined by gel shift assays. A double-stranded response element containing Gys-2 DR-lint was incubated with <italic>in vitro</italic> transcribed/translated mPPAR&#945; protein (left panel), mPPAR&#946;/&#948; protein (middle panel) and mPPAR&#947;l protein (right panel) together with <italic>in vitro</italic> transcribed/translated hRXR&#945; protein. Fold excess of specific (malic enzyme PPRE) or nonspecific (ETS oligonucleotide) cold probe is indicated.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig5" id="MO5"/></fig>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
###xml 346 350 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1109 1114 <span type="species:ncbi:10090">mouse</span>
Interestingly, using the same strategy as described above, a putative PPRE that is homologous to the consensus DR-1 sequence was identified in intron 1 of the mouse Gys-2 gene (Fig. 4a). To assess whether DR-lint was able to mediate PPAR-dependent transactivation, a 314-nucleotide genomic fragment surrounding DR-lint was cloned in front of the SV40 promoter followed by a luciferase reporter gene. In HepG2 cells treatment with the synthetic PPARalpha agonist Wy14643 induced reporter activity and this activation was further enhanced upon co-transfection of mPPARalpha (Fig. 5a). Similar inductions of reporter activity were observed for PPARbeta/delta and PPARgamma and their respective agonists (Fig. 5a). Thus, DR-lint is able to mediate PPAR-dependent transactivation, irrespective of the PPAR isotype, suggesting that it may at least be partially responsible for PPAR-dependent regulation of Gys-2 expression. Figure 5Gys-2 up-regulation by PPARs is mediated by a PPRE present in intron 1 of the Gys-2 gene (DR-lint). (a) HepG2 cells were transfected with a 314-nucleotide fragment of intron 1 of the mouse Gys-2 gene and PPAR expression vectors. Luciferase and beta-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 microM Wy14643, 5 microM L-165041 and 10 microM rosiglitazone. Error bars represent SEM. (b) Binding of the PPAR/RXR heterodimers to DR-lint as determined by gel shift assays. A double-stranded response element containing Gys-2 DR-lint was incubated with in vitro transcribed/translated mPPARalpha protein (left panel), mPPARbeta/delta protein (middle panel) and mPPARgammal protein (right panel) together with in vitro transcribed/translated hRXRalpha protein. Fold excess of specific (malic enzyme PPRE) or nonspecific (ETS oligonucleotide) cold probe is indicated.
###end p 36
###begin p 37
###xml 101 102 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 444 445 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 609 617 594 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 765 773 735 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 183 188 <span type="species:ncbi:10090">mouse</span>
Gys-2 up-regulation by PPARs is mediated by a PPRE present in intron 1 of the Gys-2 gene (DR-lint). (a) HepG2 cells were transfected with a 314-nucleotide fragment of intron 1 of the mouse Gys-2 gene and PPAR expression vectors. Luciferase and beta-galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 microM Wy14643, 5 microM L-165041 and 10 microM rosiglitazone. Error bars represent SEM. (b) Binding of the PPAR/RXR heterodimers to DR-lint as determined by gel shift assays. A double-stranded response element containing Gys-2 DR-lint was incubated with in vitro transcribed/translated mPPARalpha protein (left panel), mPPARbeta/delta protein (middle panel) and mPPARgammal protein (right panel) together with in vitro transcribed/translated hRXRalpha protein. Fold excess of specific (malic enzyme PPRE) or nonspecific (ETS oligonucleotide) cold probe is indicated.
###end p 37
###begin p 38
###xml 282 284 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5b</xref>
In agreement with the transactivation data, PPARalpha, PPARbeta/delta and PPARgamma proteins were able to specifically bind DR-lint in gel shift experiments. A retarded heterodimeric complex was observed only in the presence of both PPAR and obligate binding partner RXRalpha (Fig. 5b). The complex disappeared in the presence of an excess of cold specific oligonucleotide, but not nonspecific oligonucleotide.
###end p 38
###begin p 39
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 193 195 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6a</xref>
###xml 283 285 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6b</xref>
###xml 387 390 368 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 451 453 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6c</xref>
###xml 623 631 604 612 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 6</label>
###xml 698 705 664 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 791 792 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 812 813 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 830 831 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1003 1007 954 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a, b</italic>
###xml 1025 1026 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1068 1070 1019 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI</italic>
###xml 1089 1093 1040 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cntl</italic>
###xml 1121 1122 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 631 1219 612 1170 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">PPAR&#947;, PPAR&#946;/&#948;, and PPAR&#945; bind to the Gys-2 DR-lint <italic>in vivo</italic>. Chromatin immunoprecipitation of Gys-2 DR-lint using antibodies against mPPAR&#947; (<italic>a</italic>), mPPAR&#946;/&#948; (<italic>b</italic>) or mPPAR&#945; (<italic>c</italic>). The gene sequence spanning DR-lint and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes (<italic>a, b</italic>) or mouse liver (<italic>c</italic>). Preimmune serum was used as a control. <italic>PI</italic>, preimmune serum, <italic>Cntl</italic>, random control sequence, (<italic>d</italic>) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.</p>
###xml 631 1219 612 1170 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">PPAR&#947;, PPAR&#946;/&#948;, and PPAR&#945; bind to the Gys-2 DR-lint <italic>in vivo</italic>. Chromatin immunoprecipitation of Gys-2 DR-lint using antibodies against mPPAR&#947; (<italic>a</italic>), mPPAR&#946;/&#948; (<italic>b</italic>) or mPPAR&#945; (<italic>c</italic>). The gene sequence spanning DR-lint and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes (<italic>a, b</italic>) or mouse liver (<italic>c</italic>). Preimmune serum was used as a control. <italic>PI</italic>, preimmune serum, <italic>Cntl</italic>, random control sequence, (<italic>d</italic>) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.</p></caption>
###xml 1219 1219 1170 1170 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig6" id="MO6"/>
###xml 623 1219 604 1170 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Figure 6</label><caption><p textid="40">PPAR&#947;, PPAR&#946;/&#948;, and PPAR&#945; bind to the Gys-2 DR-lint <italic>in vivo</italic>. Chromatin immunoprecipitation of Gys-2 DR-lint using antibodies against mPPAR&#947; (<italic>a</italic>), mPPAR&#946;/&#948; (<italic>b</italic>) or mPPAR&#945; (<italic>c</italic>). The gene sequence spanning DR-lint and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes (<italic>a, b</italic>) or mouse liver (<italic>c</italic>). Preimmune serum was used as a control. <italic>PI</italic>, preimmune serum, <italic>Cntl</italic>, random control sequence, (<italic>d</italic>) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig6" id="MO6"/></fig>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 491 496 <span type="species:ncbi:10090">mouse</span>
###xml 1012 1017 <span type="species:ncbi:10090">mouse</span>
Examination of in vivo PPAR binding to DR-lint by ChIP yielded very similar results as for DR-lprom: PPARgamma was bound to DR-lint in mature 3T3-L1 adipocytes, but not in pre-adipocytes (Fig. 6a), whereas PPARbeta/delta was bound to DR-lint in both pre- and mature adipocytes (Fig. 6b). In liver, ChIP analysis demonstrated binding of PPARalpha to DR-lint in wild-type but not PPARalpha-/- mice, and binding was enhanced by fasting and Wy14643 (Fig. 6c). Together, these data indicate that mouse Gys-2 is a direct PPAR target gene and that regulation by PPARs is at least partially mediated by a PPRE present in intron 1. Figure 6PPARgamma, PPARbeta/delta, and PPARalpha bind to the Gys-2 DR-lint in vivo. Chromatin immunoprecipitation of Gys-2 DR-lint using antibodies against mPPARgamma (a), mPPARbeta/delta (b) or mPPARalpha (c). The gene sequence spanning DR-lint and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes (a, b) or mouse liver (c). Preimmune serum was used as a control. PI, preimmune serum, Cntl, random control sequence, (d) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.
###end p 39
###begin p 40
###xml 67 74 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 160 161 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 181 182 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 199 200 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 372 376 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a, b</italic>
###xml 394 395 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 437 439 407 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI</italic>
###xml 458 462 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cntl</italic>
###xml 490 491 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 381 386 <span type="species:ncbi:10090">mouse</span>
PPARgamma, PPARbeta/delta, and PPARalpha bind to the Gys-2 DR-lint in vivo. Chromatin immunoprecipitation of Gys-2 DR-lint using antibodies against mPPARgamma (a), mPPARbeta/delta (b) or mPPARalpha (c). The gene sequence spanning DR-lint and a random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes (a, b) or mouse liver (c). Preimmune serum was used as a control. PI, preimmune serum, Cntl, random control sequence, (d) Schematic overview of localization of primers used for amplification of immunoprecipitated DNA.
###end p 40
###begin p 41
###xml 0 69 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gys-2 is a novel direct target of the liver enriched factor HNF4&#945;</bold>
###xml 166 168 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4b</xref>
###xml 170 171 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">c</xref>
###xml 761 763 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7a</xref>
###xml 965 967 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7b</xref>
###xml 1094 1096 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7c</xref>
###xml 1528 1530 1464 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7d</xref>
###xml 1533 1541 1469 1477 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure 7</label>
###xml 1611 1612 1543 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1738 1739 1662 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1755 1756 1679 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1922 1923 1842 1843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2084 2085 2000 2001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 2317 2318 2229 2230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 1541 2675 1477 2571 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Gys-2 DR-lprom is a binding site for the nuclear receptor HNF4&#945;. (<italic>a</italic>) Gys-2 mRNA levels in liver of liver-specific HNF4&#945;-null (HNF4&#945;-/-) and wild-type (FLOX) mice were analyzed by qPCR (<italic>n</italic>=3 per group). (<italic>b</italic>) HepG2 cells were transfected with a reporter vector containing 553-bp of the mouse Gys-2 proximal promoter and increasing amounts of hHNF4&#945; expression vector, (<italic>c</italic>) HepG2 cells were transfected with a reporter vector containing 553 bp of the wild-type and mutated mGys-2 proximal promoter and hHNF4&#945; expression vector, (<italic>d</italic>) Chromatin immu-noprecipitation of Gys-2 DR-lprom using antibodies against HNF4&#945;. The gene sequence spanning DR-lprom and a control sequence were analyzed by PCR in the immunoprecipitated chromatin of rat primary hepatocytes. (<italic>e</italic>) HepG2 cells were transfected with a reporter vector containing 553 bp of the mouse Gys-2 proximal promoter, an expression vector for hHNF4&#945;, and increasing amounts of mPPAR&#945; expression vector. Normalized luciferase activity of the mGys-2 reporter vector in the absence of mPPAR&#945;, hHNF4&#945; and Wy 14643 was set at 1. Error bars represent SEM.</p>
###xml 1541 2675 1477 2571 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Gys-2 DR-lprom is a binding site for the nuclear receptor HNF4&#945;. (<italic>a</italic>) Gys-2 mRNA levels in liver of liver-specific HNF4&#945;-null (HNF4&#945;-/-) and wild-type (FLOX) mice were analyzed by qPCR (<italic>n</italic>=3 per group). (<italic>b</italic>) HepG2 cells were transfected with a reporter vector containing 553-bp of the mouse Gys-2 proximal promoter and increasing amounts of hHNF4&#945; expression vector, (<italic>c</italic>) HepG2 cells were transfected with a reporter vector containing 553 bp of the wild-type and mutated mGys-2 proximal promoter and hHNF4&#945; expression vector, (<italic>d</italic>) Chromatin immu-noprecipitation of Gys-2 DR-lprom using antibodies against HNF4&#945;. The gene sequence spanning DR-lprom and a control sequence were analyzed by PCR in the immunoprecipitated chromatin of rat primary hepatocytes. (<italic>e</italic>) HepG2 cells were transfected with a reporter vector containing 553 bp of the mouse Gys-2 proximal promoter, an expression vector for hHNF4&#945;, and increasing amounts of mPPAR&#945; expression vector. Normalized luciferase activity of the mGys-2 reporter vector in the absence of mPPAR&#945;, hHNF4&#945; and Wy 14643 was set at 1. Error bars represent SEM.</p></caption>
###xml 2675 2675 2571 2571 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="18_2007_Article_7006_Fig7" id="MO7"/>
###xml 1533 2675 1469 2571 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Figure 7</label><caption><p textid="42">Gys-2 DR-lprom is a binding site for the nuclear receptor HNF4&#945;. (<italic>a</italic>) Gys-2 mRNA levels in liver of liver-specific HNF4&#945;-null (HNF4&#945;-/-) and wild-type (FLOX) mice were analyzed by qPCR (<italic>n</italic>=3 per group). (<italic>b</italic>) HepG2 cells were transfected with a reporter vector containing 553-bp of the mouse Gys-2 proximal promoter and increasing amounts of hHNF4&#945; expression vector, (<italic>c</italic>) HepG2 cells were transfected with a reporter vector containing 553 bp of the wild-type and mutated mGys-2 proximal promoter and hHNF4&#945; expression vector, (<italic>d</italic>) Chromatin immu-noprecipitation of Gys-2 DR-lprom using antibodies against HNF4&#945;. The gene sequence spanning DR-lprom and a control sequence were analyzed by PCR in the immunoprecipitated chromatin of rat primary hepatocytes. (<italic>e</italic>) HepG2 cells were transfected with a reporter vector containing 553 bp of the mouse Gys-2 proximal promoter, an expression vector for hHNF4&#945;, and increasing amounts of mPPAR&#945; expression vector. Normalized luciferase activity of the mGys-2 reporter vector in the absence of mPPAR&#945;, hHNF4&#945; and Wy 14643 was set at 1. Error bars represent SEM.</p></caption><graphic position="anchor" xlink:href="18_2007_Article_7006_Fig7" id="MO7"/></fig>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 1498 1501 <span type="species:ncbi:10116">rat</span>
###xml 1710 1714 <span type="species:ncbi:10090">mice</span>
###xml 1835 1840 <span type="species:ncbi:10090">mouse</span>
###xml 2291 2294 <span type="species:ncbi:10116">rat</span>
###xml 2397 2402 <span type="species:ncbi:10090">mouse</span>
Gys-2 is a novel direct target of the liver enriched factor HNF4alpha. As explained above, PPARalpha caused a reduction in Gys-2 promoter activity via DR-lprom (Fig. 4b, c). A similar decrease of promoter activity in response to PPARalpha despite the presence of a putative PPRE has been reported for other genes. Indeed, it was found that PPARalpha decreases expression of the apoCIII and transferrin genes via competition with the HNF4alpha. Since HNF4alpha is known to recognize DR-1 sequences as well, we examined whether HNF4alpha might control the expression of Gys-2 in liver, possibly via DR-lprom. Gys-2 mRNA levels were markedly decreased in liver-specific HNF4alphanull mice, thus supporting a role for HNF4alpha in regulating Gys-2 expression (Fig. 7a). In transactivation assays using the Gys-2 promoter, HNF4alpha markedly activated reporter activity, suggesting the presence of a HNF4alpha response element within the 0.55-kb promoter fragment (Fig. 7b). Mutating DR-lprom resulted in an approximately 50 % reduction in HNF4alpha-dependent activation of the Gys-2 promoter (Fig. 7c), which suggests that (a) HNF4alpha responsiveness is partially mediated by DR-lprom, or (b) the mutations with DR-lprom only partially disabled HNF4alpha responsiveness. Regardless of these explanations, these data suggest that HNF4alpha directly regulates the hepatic expression of Gys-2 at least partially via DR-lprom. Finally, ChIP clearly showed HNF4alpha binding to DR-lprom but not DR-lint in rat primary hepatocytes (Fig. 7d). Figure 7Gys-2 DR-lprom is a binding site for the nuclear receptor HNF4alpha. (a) Gys-2 mRNA levels in liver of liver-specific HNF4alpha-null (HNF4alpha-/-) and wild-type (FLOX) mice were analyzed by qPCR (n=3 per group). (b) HepG2 cells were transfected with a reporter vector containing 553-bp of the mouse Gys-2 proximal promoter and increasing amounts of hHNF4alpha expression vector, (c) HepG2 cells were transfected with a reporter vector containing 553 bp of the wild-type and mutated mGys-2 proximal promoter and hHNF4alpha expression vector, (d) Chromatin immu-noprecipitation of Gys-2 DR-lprom using antibodies against HNF4alpha. The gene sequence spanning DR-lprom and a control sequence were analyzed by PCR in the immunoprecipitated chromatin of rat primary hepatocytes. (e) HepG2 cells were transfected with a reporter vector containing 553 bp of the mouse Gys-2 proximal promoter, an expression vector for hHNF4alpha, and increasing amounts of mPPARalpha expression vector. Normalized luciferase activity of the mGys-2 reporter vector in the absence of mPPARalpha, hHNF4alpha and Wy 14643 was set at 1. Error bars represent SEM.
###end p 41
###begin p 42
###xml 70 71 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 197 198 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 214 215 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 381 382 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 543 544 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 776 777 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
###xml 750 753 <span type="species:ncbi:10116">rat</span>
###xml 856 861 <span type="species:ncbi:10090">mouse</span>
Gys-2 DR-lprom is a binding site for the nuclear receptor HNF4alpha. (a) Gys-2 mRNA levels in liver of liver-specific HNF4alpha-null (HNF4alpha-/-) and wild-type (FLOX) mice were analyzed by qPCR (n=3 per group). (b) HepG2 cells were transfected with a reporter vector containing 553-bp of the mouse Gys-2 proximal promoter and increasing amounts of hHNF4alpha expression vector, (c) HepG2 cells were transfected with a reporter vector containing 553 bp of the wild-type and mutated mGys-2 proximal promoter and hHNF4alpha expression vector, (d) Chromatin immu-noprecipitation of Gys-2 DR-lprom using antibodies against HNF4alpha. The gene sequence spanning DR-lprom and a control sequence were analyzed by PCR in the immunoprecipitated chromatin of rat primary hepatocytes. (e) HepG2 cells were transfected with a reporter vector containing 553 bp of the mouse Gys-2 proximal promoter, an expression vector for hHNF4alpha, and increasing amounts of mPPARalpha expression vector. Normalized luciferase activity of the mGys-2 reporter vector in the absence of mPPARalpha, hHNF4alpha and Wy 14643 was set at 1. Error bars represent SEM.
###end p 42
###begin p 43
###xml 0 82 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cross-talk between PPAR&#945; and HNF4&#945; in the transcriptional control of Gys-2</bold>
###xml 582 584 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7e</xref>
Cross-talk between PPARalpha and HNF4alpha in the transcriptional control of Gys-2. Whereas HNF4alpha activates the Gys-2 promoter via DR-lprom, PPARalpha does the opposite, suggesting that PPARalpha may interfere with Gys-2 promoter activation by HNF4alpha. To examine whether this is the case, the effect of PPARalpha on HNF4alpha-mediated transactivation of the 0.55-kb Gys-2 promoter was studied. PPARalpha activation significantly reduced HNF4alpha-dependent transactivation, indicating competition between HNF4alpha and PPARalpha in the regulation of the Gys-2 promoter (Fig. 7e). As already mentioned above, we failed to find any evidence for binding of PPARalpha to DR-lprom in hepatocytes. Thus, the inhibitory effect of PPARalpha on transcriptional activation of Gys-2 by HNF4alpha likely does not occur via competition with HNF4alpha for actual binding to DR-lprom.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
In the present study, we have identified the mouse Gys-2 gene as a direct PPAR and HNF4alpha target gene. We have shown that the effects of PPARs and HNF4alpha on Gys-2 expression occur via two distinct response elements. Indeed, while transcriptional activation of the Gys-2 gene by PPARs was found to be mediated by a PPRE present in intron 1 of the mGys-2 gene (DR-lint), the stimulatory effect of HNF4alpha was mediated by a response element in the immediate upstream promoter (DR-lprom).
###end p 45
###begin p 46
Our data are suggestive of the following scenario. In liver, which expresses high amounts of HNF4alpha, DR-lprom is occupied by HNF4alpha but not PPARalpha, while DR-lint is bound by PPARalpha but not HNF4alpha. Hence, HNF4alpha and PPARalpha activate Gys-2 expression via different response elements. Nevertheless, important negative cross-talk between the two nuclear receptors was observed. In the absence of any mutual binding to the response elements, it can be hypothesized that competition may take place at the level of binding to common co-activator proteins in a mechanism that is often referred to as squelching. In adipose tissue, which does not express HNF4alpha, DR-lprom is occupied by PPARbeta/delta and PPARgamma, but this does not result in transcriptional activation. Rather, transactivation occurs via binding of PPARbeta/delta and PPARgamma to DR-lint.
###end p 46
###begin p 47
###xml 196 198 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 436 438 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 738 747 710 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 500 505 <span type="species:ncbi:9606">human</span>
Our data indicate that HNF4alpha is an extremely powerful activator of mouse Gys2 transcription, explaining the marked reduction in hepatic Gys-2 expression in liver-specific HNF4alpha-null mice [35]. As mentioned above, regulation of mGys-2 expression by HNF4alpha at least partially occurs via DR-lprom. A recent study that combined ChIP with promoter micro-arrays showed that the Gys-2 promoter is bound by HNF4alpha in human liver [36], thus establishing Gys-2 as a direct target of HNF4alpha in human as well. It is not very clear why disabling the DR-lprom reduced HNF4alpha-dependent trans-activation by only 50 %. It is possible that the 0.55-kb Gys-2 promoter fragment contains an additional HNF4alpha response element, although in silico analysis failed to reveal such an element. Alternatively, it is possible that mutating the wild-type DR-lprom (AGGCCAAAGGCCA) into a mutated DR-lprom (AGGCCTTTGGCCA) only partially disabled the response element.
###end p 47
###begin p 48
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 192 197 <span type="species:ncbi:9606">human</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 216 219 <span type="species:ncbi:10116">rat</span>
###xml 277 280 <span type="species:ncbi:10116">rat</span>
###xml 315 320 <span type="species:ncbi:9606">human</span>
While functional PPREs are commonly located within regulatory sequences, i.e., proximal promoters, PPREs have also been identified in intronic sequences. Examples are PPREs within intron 3 of human/mouse Angptl4 and rat peroxisomal thiolase B genes, and within intron 1 of the rat acyl-CoA binding protein gene and human carnitine palmitoyltransferase 1A [2-5]. Our data demonstrate that regulation of Gys-2 expression by PPARs is also mediated by an intronic PPRE.
###end p 48
###begin p 49
###xml 75 82 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 161 163 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 165 167 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 363 365 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 557 559 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 664 666 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 879 881 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 883 885 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 887 889 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 1391 1397 1320 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 1608 1616 1521 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 1182 1186 <span type="species:ncbi:10090">mice</span>
###xml 1598 1602 <span type="species:ncbi:10090">mice</span>
In the past few years, our understanding of the function of PPARbeta/delta in vivo has improved greatly thanks to studies using various transgenic mouse models [19, 37]. At the level of metabolism, PPARbeta/delta over-expression promotes skeletal muscle fatty acid oxidation and type I fiber content in mice, resulting in improved endurance exercise performance [22]. Conversely, deletion of PPARbeta/delta in cardiomyocytes is associated with impaired fatty acid oxidation and expression of fatty acid oxidative genes, whereas glucose uptake is increased [38]. In WAT, PPARbeta/delta stimulates fatty acid oxidation and uncoupling, thereby diminishing adiposity [21]. It is thus clear that PPARbeta/delta plays a pivotal role in governing fatty acid oxidation in a variety of tissues. In contrast, data linking PPARbeta/delta to regulation of glucose homeostasis remain scarce [20, 39, 40]. Our data reveal that PPARbeta/delta is a critical regulator of the adipose expression of the Gys-2 gene. Furthermore, micro-array and qPCR analysis indicated that expression of numerous other genes involved in lipid and glucose metabolism was markedly down-regulated in PPARbeta/delta-null mice, including GLUT4, p85, and CD36. Since PPARgamma and PGC-lalpha were significantly down-regulated as well, it is possible that many of the observed changes are not linked to the absence of PPARbeta/delta per se but rather reflect indirect effects mediated via decreased PPARgamma and PGC-lalpha mRNA. Although such an effect may contribute to some extent to the down-regulation of Gys-2 in PPARdelta/delta-null mice, the in vitro studies leave no doubt that Gys-2 is a direct target gene of PPARbeta/delta, as well as of PPARgamma.
###end p 49
###begin p 50
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 958 960 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 962 964 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 930 935 <span type="species:ncbi:9606">human</span>
###xml 940 945 <span type="species:ncbi:10090">mouse</span>
Glycogen is stored in many tissues, yet it is particularly abundant in liver, muscle, and adipose tissue. In liver, glycogen serves to maintain blood glucose levels between meals, while skeletal muscle glycogen is used to fuel muscle contractions. In contrast, adipose tissue glycogen serves as a source of glycerol 3-phosphate, which is required for (re)-esterification of fatty acids into triglycerides [41]. Several alternative pathways exist to produce glycerol 3-phosphate, including synthesis from glucose, and conversion of gluconeogenic precursors (glyceroneogenesis). Since expression and activity of glycerol kinase are very low in adipose tissue [42], direct phosphorylation of glycerol is not considered as a major pathway to generate glycerol 3-phosphate. However, recent studies suggest that this may change after treatment with synthetic PPARgamma agonists, which markedly up-regulate glycerol kinase expression in human and mouse adipocytes [11, 42]. In fact, it has been hypothesized that stimulation of glycerol kinase expression by TZDs, resulting in increased fatty acid re-esterification, may at least partially account for the suppressive effect of TZDs on plasma free fatty acid levels. Stimulation of fatty acid esterification is part of a general lipogenic and adipogenic effect of PPARgamma in the adipocyte. Since adipose glycogen stores yield glycerol 3-phosphate as a precursor for fatty acid (re-)esterification, up-regulation of Gys-2 expression by PPARgamma can be placed in the context of the lipogenic role of PPARgamma in the adipocyte, which is aimed at promoting energy storage.
###end p 50
###begin p 51
Besides contributing to lipogenesis, synthesis of glycogen permits continued uptake of glucose into cells. Accordingly, it can be speculated that up-regulation of adipose Gys-2 by PPARgamma might partially account for the stimulation of glucose uptake into adipocytes by PPARgamma agonists.
###end p 51
###begin p 52
###xml 224 226 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 228 230 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 348 350 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
It is currently still ambiguous whether PPARbeta/delta serves a general anabolic or catabolic function in the adipocyte. On the one hand, it has been reported that PPARbeta/delta promotes fatty acid oxidation in adipocytes [20, 21]. On the other hand, PPARbeta/delta also seems to have a facilitative, yet important role in lipo- and adipogenesis [43]. As discussed above for PPARgamma, up-regulation of Gys-2 expression by PPARbeta/delta may indicate a role for PPARbeta/delta in fatty acid (re-)esterification, thus contributing to a lipogenic role for PPARbeta/delta.
###end p 52
###begin p 53
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 876 878 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 879 881 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 1380 1382 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 1454 1456 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
###xml 1273 1277 <span type="species:ncbi:10090">mice</span>
###xml 1308 1314 <span type="species:ncbi:9606">humans</span>
###xml 1497 1505 <span type="species:ncbi:9606">patients</span>
###xml 1551 1555 <span type="species:ncbi:10090">mice</span>
The highest levels of glycogen are found in liver and fluctuate with nutritional status. The hepatic synthesis of glycogen from glucose is catalyzed by Gys-2 [44]. Remarkably, expression of Gys-2 in liver increases during fasting, at the same time when glycogen stores are actively broken down [32]. The reason behind this seemingly counterintuitive regulation is not very clear, but it may serve to prime the glucose synthesizing system for when dietary glucose becomes available again. In the absence of PPARalpha, we observed that the expression of Gys-2 drops markedly during prolonged fasting and refeeding. The reduced Gys-2 expression is likely responsible for the diminished rate of glycogen formation upon refeeding, as observed by us and previously by others. Indeed, the effect of PPARalpha deletion on liver glycogen is minor except under conditions of refeeding [30-32]. It has been reported that after a short-term fast the gluconeogenic flux in PPARalpha-null mice is directed more towards glycogen, leading to a decrease in hepatic glucose output. However, it is unclear what happens to the gluconeogenic flux toward glycogen in the fasted-refed state, although our and other data clearly indicate that total glycogen synthesis is decreased in PPARalpha-/- mice. Mutation of the GYS2 gene in humans leads to lower hepatic glycogen levels and fasting hypoglycemia [45], biochemical features that are also observed in PPARalpha-/- animals [31]. However, opposite to that observed in patients with a dysfunctional GYS2 gene, PPARalpha-/- mice show low plasma ketones, which is explained by the stimulatory effect of PPARalpha on fatty acid oxidation and ketogenesis.
###end p 53
###begin p 54
###xml 125 127 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 129 131 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Overall, our data suggest that the decreased hepatic glycogen levels in PPARalpha-/- and liver-specific HNF4alpha-null mice [28, 35] may be due to decreased activation of Gys-2 expression via DR-lint and DR-lprom, respectively. Although PPARalpha and HNF4alpha stimulate Gys-2 expression via different response elements, important interplay exist between signaling of the two nuclear receptors.
###end p 54
###begin p 55
In conclusion, we show that Gys-2 is a direct target gene of PPARs. Transcriptional regulation is achieved via a PPRE present in the first intron. An additional direct repeat response element identified in the Gys-2 promoter mediates transactivation by HNF4alpha.
###end p 55
###begin title 56
Acknowledgement
###end title 56
###begin p 57
###xml 428 433 <span type="species:ncbi:9606">Human</span>
###xml 495 500 <span type="species:ncbi:9606">Human</span>
We would like to thank Marco Alves for the synthesis of LI65041 compound, Mechteld Grootte-Bromhaar and Jolanda van der Meijde for performing the micro-array experiment. This study was supported by the Netherlands Organization for Scientific Research (NWO), with additional support from the Dutch Diabetes Foundation, the Royal Netherlands Academy of Art and Sciences (KNAW), Wageningen Center for Food Sciences, the Center for Human Nutrigenomics, the Swiss National Science Foundation and the Human Frontier Science Program.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Peroxisome proliferatoractivated receptors: nuclear control of metabolism
###end article-title 59
###begin article-title 60
###xml 100 103 <span type="species:ncbi:10116">rat</span>
Functional characterization of a peroxisome proliferator responseelement located in the intron 3 of rat peroxisomal thiolase B gene
###end article-title 60
###begin article-title 61
###xml 180 186 <span type="species:ncbi:9606">humans</span>
The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents
###end article-title 61
###begin article-title 62
The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment
###end article-title 62
###begin article-title 63
###xml 109 114 <span type="species:ncbi:9606">human</span>
An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A
###end article-title 63
###begin article-title 64
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 42 45 <span type="species:ncbi:10116">rat</span>
Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding
###end article-title 64
###begin article-title 65
Peroxisome proliferatoractivated receptor alpha mediates the adaptive response to fasting
###end article-title 65
###begin article-title 66
###xml 136 141 <span type="species:ncbi:10090">mouse</span>
Acritical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalphanull mouse as a model of fatty acid oxidation disorders
###end article-title 66
###begin article-title 67
The peroxisome proliferator- activated receptor alpha regulates amino acid metabolism
###end article-title 67
###begin article-title 68
Peroxisome proliferator-activated receptor alpha target genes
###end article-title 68
###begin article-title 69
PPARalpha governs glycerol metabolism
###end article-title 69
###begin article-title 70
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Global suppression of IL- 6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate
###end article-title 70
###begin article-title 71
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage
###end article-title 71
###begin article-title 72
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma
###end article-title 72
###begin article-title 73
A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes
###end article-title 73
###begin article-title 74
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus
###end article-title 74
###begin article-title 75
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse
###end article-title 75
###begin article-title 76
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
###end article-title 76
###begin article-title 77
Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability
###end article-title 77
###begin article-title 78
Activation of peroxisome proliferator-activated receptor delta induces fatty acid betaoxidation in skeletal muscle and attenuates metabolic syndrome
###end article-title 78
###begin article-title 79
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
###end article-title 79
###begin article-title 80
Regulation of muscle fiber type and running endurance by PPARdelta
###end article-title 80
###begin article-title 81
###xml 122 126 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet
###end article-title 81
###begin article-title 82
Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway
###end article-title 82
###begin article-title 83
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth
###end article-title 83
###begin article-title 84
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta
###end article-title 84
###begin article-title 85
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action
###end article-title 85
###begin article-title 86
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis
###end article-title 86
###begin article-title 87
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein Edeficient mouse hepatocytes
###end article-title 87
###begin article-title 88
Peroxisome-proliferator-activated receptor- alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin
###end article-title 88
###begin article-title 89
Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production
###end article-title 89
###begin article-title 90
###xml 8 15 8 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo</italic>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast
###end article-title 90
###begin article-title 91
###xml 13 22 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
NUBIScan, an in silico approach for prediction of nuclear receptor response elements
###end article-title 91
###begin article-title 92
Prediction of nuclear hormone receptor response elements
###end article-title 92
###begin article-title 93
Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis
###end article-title 93
###begin article-title 94
Control of pancreas and liver gene expression by HNF transcription factors
###end article-title 94
###begin article-title 95
Critical roles of PPAR beta/delta in keratinocyte response to inflammation
###end article-title 95
###begin article-title 96
Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy
###end article-title 96
###begin article-title 97
The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells
###end article-title 97
###begin article-title 98
PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle
###end article-title 98
###begin article-title 99
Regulation of glycogen synthase in muscle and adipose tissue during fasting and refeeding
###end article-title 99
###begin article-title 100
Afutile metabolic cycle activated in adipocytes by antidiabetic agents
###end article-title 100
###begin article-title 101
PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation
###end article-title 101
###begin article-title 102
###xml 49 57 <span type="species:ncbi:9606">children</span>
Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0
###end article-title 102
###begin article-title 103
Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia
###end article-title 103
###begin p 104
Received 8 January 2007; received after revision 28 February 2007; accepted 20 March 2007
###end p 104
###begin p 105
S. Mandard, R. Stienstra: These authors equally contributed to this work.
###end p 105

